

A Member of Trinity Health

# Pharmacy Residency Manual Loyola University Medical Center



#### **Table of Contents**

Letter of Welcome

Introduction

Diversity, Equity, and Inclusion

Loyola University Medical Center General Information

Loyola University Medical Center Mission Statement

**Department of Pharmacy Services** 

**Organizational Chart** 

The Loyola University Medical Center Pharmacy Residency Programs

PGY1 Purpose PGY2 Purpose

LUMC Pharmacy Residency Experience

**LUMC Residency Program Leadership** 

**LUMC Residency Program Preceptors** 

**All Programs Rotation List** 

**Longitudinal Experiences and Administrative Rotations** 

ED On Call

Code Blue Response
Code Stroke Response

Staffing Responsibilities and Requirements

**PGY1 Staffing** 

PGY2 Critical Care Staffing

**PGY2 SOT Staffing** 

**Evaluation Procedures** 

Pharmacy Residency Certificate

Pharmacy Residency Position Descriptions

**PGY1 Resident Mentor** 

Pharmacy Residency Committees

General Employment Information and Pharmacy Resident Benefits

Benefits Time Off

Attendance and Leave Policies

Illinois Licensure

Performance Improvement Plans (PIP)

Corrective Disciplinary Action

Moonlighting
Duty Hours

**Travel Expenses Policy** 

Appendix 1: PGY1 Pharmacy Residency Program Overview

Appendix 2: <u>PGY2 Critical Care Pharmacy Residency Program Overview</u>
Appendix 3: PGY2 Solid Organ Transplant Pharmacy Residency Program

Overview

Appendix 4: PGY2 Infectious Diseases Pharmacy Residency Program

Overview

Appendix 5: <u>Duty Hour Requirements</u>

Appendix 6: Additional Pharmacy Resident Benefits and Services

Additional appendices

Appendix 7: Education Committee Guidance

Appendix 8: Resident Recruitment and Hiring Process

Appendix 9: Preceptor Development Policy



#### Dear Resident.

On behalf of the Department of Pharmacy Services, welcome to Loyola University Medical Center! As you progress through your residency year, we ask you to be mindful of the mission and core values of Loyola University Medical Center. We use these values every day to guide us in all that we do, including residency training.

#### **Our Mission:**

The Pharmacy department is focused on excellent patient care experiences through collaboration with other healthcare professionals, safe and effective medication optimization and distribution, use of innovative technology, and evidence-based medicine. We foster a culture of teamwork, commitment to quality, courtesy, compassion, education and respecting the dignity and confidentiality of the patient. The Pharmacy department is committed to consistently delivering the highest quality patient care and services through best practices of both clinical and operational programs.

#### **Our Core Values:**

**Reverence:** We honor the sacredness and dignity of every person.

**Commitment to Those Who are Poor:** We stand with and serve those who are poor, especially those most vulnerable.

**Safety:** We embrace a culture that prevents harm and nurtures a healing, safe environment for all. **Justice:** We foster relationships to promote the common good, including sustainability of Earth. **Stewardship:** We honor our heritage and hold ourselves accountable for the human, financial and natural resources entrusted to our care.

**Integrity:** We are faithful to who we say we are.

We believe you've made a great career choice in choosing to do your residency at Loyola University Medical Center. We want you to be successful in all that you do. We want you to be an excellent representative of this residency program and department.

Please do not hesitate to ask for help from any member of our department.

Sincerely,

Travis Hunerdosse, PharmD, MBA Lisa Peters, PharmD
Regional Chief Pharmacy Officer Regional Director of Clinical Pharmacy Services

and Residency Programs

Kevin Chang, PharmD, BCCCP

Grace E. Benanti, PharmD, BCCCP

PGY1 Residency Program Director PGY2 Critical Care Residency Program Director

Meghan Walsh, PharmD, BCTXP

PGY2 Solid Organ Transplant Residency

Program Director

Caleb Rux, PharmD, BCIDP

PGY2 Infectious Diseases Residency Program

Director



#### Introduction

This manual is a guide and reference for all pharmacy residents and residency preceptors. The purpose of written policies is to establish guidelines regarding Loyola University Medical Center (sometimes referred to as Loyola or LUMC) and the responsibilities expected of a pharmacy resident. This policy manual, however, is not a contract of employment or a guarantee of future training or employment for a particular period. Contracts of employment are recognized only when they are in writing and signed by a designated official of Loyola University Medical Center.

Please read the contents of this manual carefully. This is one of the many channels of communication we maintain to create a productive learning environment. All pharmacy residents should use this manual as a reference to answer questions regarding all of our policies. We hope that the use of these policies will assist in working in a fair and equitable manner.

This manual is used as an ongoing document that will be amended and updated as needed. Pharmacy residents are expected to become familiar with and comply with all policies set forth in this manual, as well as those of Loyola Medicine and Trinity Health.

# Diversity, Equity, and Inclusion

The LUMC Pharmacy Residency Department values the power of human difference to foster innovation, remove barriers, and transform lives. We are dedicated to advancing health and racial equity and creating a culture of inclusion through continued education, training, and living our Core Values with the people and communities served.

Loyola abides by all applicable provisions of Federal, State and Local law. Loyola does not discriminate in its employment policies and practices on the basis of race, color, religion, (except where religion is a *bona fide* occupational qualification for the job), national origin or ancestry, gender, sexual orientation, age, marital status, veteran's status, or any other classification protected by law. Otherwise, qualified individuals are not discriminated against on the basis of physical or mental disabilities. Loyola will not tolerate racial, sexual or other forms of harassment of students, faculty, employees or patients and has established policies and procedures to promptly address any complaints.

# **Loyola Medicine – General information**

Loyola Medicine, which is a member of Trinity Health, is multi-campus organization that includes the Loyola University Medical Center campus in Maywood (547 inpatient beds; the Cardinal Bernardin Cancer Center, the Ronald McDonald Children's Hospital of Loyola, the Burn/Trauma Center, and the Center for Heart & Vascular Medicine), MacNeal Hospital in Berwyn and Gottlieb Memorial Hospital in Melrose Park. Loyola offers a wide range of medical, surgical and obstetrical services including many specialty services. Loyola University Medical Center is the only academic teaching hospital in the western suburbs of Chicago and is also a large referral center for this area. Loyola is an accredited Level I Trauma Center, a Burn Center, a Comprehensive Stroke Center, and is served by an aeromedical program that transports patients from up to 150 miles away to Loyola. Specialty services include solid organ transplantation, burn care, cardiovascular surgery, oncology, women's health, primary care,



and pediatrics among many others. Loyola University Medical Center houses nine discrete critical care units (neurological, medical, cardiovascular, cardiac, surgical/trauma, bone marrow transplant, burn, pediatric, and neonatal). Also located on the Maywood campus is the Loyola University Chicago Stritch School of Medicine and the Loyola University Chicago Marcella Niehoff School of Nursing. In addition to the Maywood, Berwyn and Melrose Park campuses, Loyola has an extensive network of primary and specialty care centers in Chicago's western and southwestern suburbs.

The Loyola Medicine promise, "to be at our best when things are at their worst," encapsulates Loyola's Catholic-Jesuit, ethical and spiritual values. These Magis values of care, concern, cooperation, and respect for others suggest the spirit of generous excellence in which we believe our ministry should be carried forward. These key values form the heart of our Catholic identity and Jesuit mission and guide our employees including faculty members, residents, and fellows.

#### **LUMC Mission Statement**

Loyola University Medical Center is committed to excellence in patient care and the education of health professionals. We believe that our Catholic heritage and Jesuit traditions of ethical behavior, academic distinction, and scientific research lead to new knowledge and advance our healing mission in the communities we serve. We believe that thoughtful stewardship, learning and constant reflection on experience improve all we do as we strive to provide the highest quality health care.

We believe in God's presence in all our work. Through our care, concern, respect and cooperation, we demonstrate this belief to our patients and families, our students, and each other. To fulfill our mission, we foster an environment that encourages innovation, embraces diversity, respects life, and values human dignity.

We are committed to going beyond the treatment of disease, to be at our best when things are at their worst.



# Loyola University Medical Center Department of Pharmacy Services

**Regional Chief Pharmacy Officer** 

Travis Hunerdosse, PharmD, MBA Travis.Hunerdosse@luhs.org

**Director, Pharmacy Operations** 

Rachael Fleagle Miller, PharmD, MS Rachael.fleaglemiller@luhs.org

Regional Director of Medication Safety, Compliance, and IT

Sara Beyer, PharmD sara.beyer@lumc.edu

**Clinical Pharmacy Coordinator** 

Kevin Chang, PharmD, BCCCP Kevin.Chang001@luhs.org

Pharmacy Operations Manager, Central Pharmacy/OR/ASC

Christopher J. Caracci, PharmD, MPA, DPLA Chris.caracci@luhs.org

Pharmacy Operations Manager, IV Room and Pediatric Satellite Pharmacy

Shawna Cook, MS, PharmD, BCPS, BCSCP Shawna.Cook001@luhs.org

Regional Director of Ambulatory Pharmacy Services, Loyola Medicine

Joe Hegazin, PharmD joseph.hegazin@luhs.org

Regional Director of Clinical Pharmacy Services and Residency Programs

Lisa Peters, PharmD Lisa.peters@luhs.org

Manager, Pharmacy Informatics

John Ilic, PharmD, MBA

jilic@lumc.edu


Pharmacy Manager, Clinical Services
Lindsay Wittekindt, PharmD, BCPS, BCPPS
LWittekindt@lumc.edu



# **Organizational Chart**



# **Pharmacy Organizational Structure**





# **Loyola University Medical Center Pharmacy Residency Programs**

#### **PGY1 Purpose**

PGY1 residency programs build upon Doctor of Pharmacy (PharmD) education and outcomes to develop pharmacist practitioners with knowledge, skills, and abilities as defined in the educational competency areas, goals, and objectives. Residents who successfully complete PGY1 residency programs will be skilled in diverse patient care, practice management, leadership, and education and be prepared to provide patient care, seek board certification in pharmacotherapy (i.e., BCPS), and pursue advanced education and training opportunities including postgraduate year two (PGY2) residencies.

# **PGY2 Purpose**

PGY2 residency programs build upon Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency training to develop pharmacist practitioners with knowledge, skills, and abilities as defined in the educational competency areas, goals, and objectives for advanced practice areas. Residents who successfully complete PGY2 residency programs are prepared for advanced patient care or other specialized positions and board certification in the advanced practice area, if available.

# **LUMC Pharmacy Residency Experience**

Loyola University Medical Center offers a one-year post-graduate year one (PGY1) pharmacy residency, a one-year post-graduate year two (PGY2) Critical Care (CC) pharmacy residency, a one-year post-graduate year two (PGY2) Infectious Diseases pharmacy residency, and a one-year post-graduate year two (PGY2) Solid Organ Transplant (SOT) pharmacy residency. The number of positions for each residency program may vary and are subject to change year-to-year. The program is designed to offer a wide variety of clinical practice experiences in critical care medicine and surgery, general medicine, cardiology, pediatrics, transplantation, hematology/oncology and infectious diseases. Graduates of this program will be well-rounded practitioners with the skills to practice in a variety of care settings. Graduates will possess the knowledge and critical thinking skills to function as members of a multidisciplinary team to provide patient-centered care to patients with a wide variety of disease states.

Pharmacy residents are provided the opportunity to accelerate their growth beyond entry-level professional competence in patient-centered care and in pharmacy operational services, and to further the development of leadership skills that can be applied in any position and in any practice setting. Pharmacy residents acquire knowledge required for skillful problem-solving, refine their problem-solving strategies, strengthen their professional values and attitudes, and advance the growth of their clinical judgment.



# **LUMC Residency Program Leadership**

Lisa Peters, PharmD Regional Director of Clinical Pharmacy Services and Residency Programs

Kevin Chang, PharmD, BCCCP PGY1 Residency Program Director

Grace E. Benanti, PharmD, BCCCP PGY2 Critical Care Residency Program Director 2025-2026

Meghan Walsh, PharmD, BCTXP PGY2 Solid Organ Transplant Residency Program Director

Caleb Rux, PharmD, BCIDP PGY2 Infectious Diseases Residency Program Director Kelli Covington, PharmD, BCPS, BCPPS PGY1 Residency Program Coordinator

Shannon Kuhrau, PharmD, BCCCP PGY2 Critical Care Residency Program Coordinator 2025-2026 Residency Program Director 2026

Kaley Deichstetter, PharmD, BCCCP PGY2 Critical Care Residency Program Coordinator

Claire Schmidt, PharmD, BCTXP PGY2 Solid Organ Transplant Residency Program Coordinator

Jenny Novak, PharmD PGY2 Solid Organ Transplant Residency Program Coordinator

Jordan Crew, PharmD PGY2 Infectious Diseases Residency Program Coordinator

Jessica Ni, PharmD, BCIDP PGY2 Infectious Diseases Residency Program Coordinator



# **LUMC Residency Preceptors**

**General Medicine and Cardiology** 

Jeffrey Wieczorkiewicz, PharmD, BCPS General Medicine Jeffery.wieczorkiewicz@luhs.org

Julie (Yuliya) Genkina, PharmD, BCPS General Medicine Yuliya.genkina@luhs.org

**Emergency Medicine** 

Neal Lyons, PharmD Emergency Medicine Neal.Lyons@luhs.org

**Infectious Diseases** 

Caleb Rux, PharmD, BCIDP Transplant Infectious Diseases Caleb.Rux@luhs.org Alaa Sulh, PharmD General Medicine alaa.sulh@luhs.org

Anjali Lamba, PharmD, BCPS Cardiology alamba@lumc.edu

Maria Hartwig, PharmD, BCCCP Emergency Medicine Maria.Hartwig@luhs.org

Jessica Ni, PharmD, BCIDP Infectious Diseases Jessica.Ni@luhs.org

Jordan Crew, PharmD Infectious Diseases Jordan.Crew@luhs.org



**Adult Critical Care** 

Jordan Meckel, PharmD, BCCCP Neurosciences ICU Jordan.Meckel@luhs.org

Grace E. Benanti, PharmD, BCCCP Medical ICU

Grace.Benanti@luhs.org

Erica Konopka, PharmD Surgical-Trauma ICU/Critical Care Float

Erica.Konopka@luhs.org

Kaley Deichstetter, PharmD, BCCCP

Critical Care Float

Kaley.Deichstetter@luhs.org

**Pediatrics** 

Kelli Covington, PharmD, BCPS, BCPPS General Pediatrics/Pediatric ICU Kelli.Covington@luhs.org

**Solid Organ Transplant** 

Ellie Langhammer, PharmD Thoracic Transplant Ellie.langhammer@luhs.org

Meghan Walsh, PharmD, BCTXP Abdominal Transplant Meghan.Walsh001@luhs.org

Michelle Fine, PharmD, BCPS, BCACP Heart Transplant/Advanced Heart Failure Michelle.Fine@luhs.org

JinJoo Chung, PharmD Heart Transplant/Advanced Heart Failure JinJoo.Chung@luhs.org

Oncology

Sanja Zepcan, PharmD, BCPS Bone Marrow Transplant Sanja.Zepcan@luhs.org

**Acute Care** 

John Rubino, PharmD Clinical Float John.rubino001@luhs.org Kevin Chang, PharmD, BCCCP Surgical-Trauma ICU Kevin.Chang001@luhs.org

RaeAnn Hirschy, PharmD, BCCCP Cardiovascular ICU RaeAnn.Hirschv@luhs.org

Shannon Kuhrau, PharmD, BCCCP Burn ICU

Shannon.Kuhrau@luhs.org

Andrew DeSio, PharmD, BCCCP, BCIDP, BCCP, BCPS Critical Care Float Andrew.Desio@luhs.org

Pamela Nicoski, PharmD, BCPS, BCPPS Neonatal ICU

pnicosk@lumc.edu

Claire Schmidt, PharmD, BCTXP Abdominal Transplant Claire.Schmidt@luhs.org

Shelly Goyal, PharmD, BCTXP Abdominal Transplant Shelly.Goyal@luhs.org

Jenny Novak, PharmD Thoracic Transplant Jenny.novak@luhs.org

Emily Rux, PharmD, BCOP Hematology/Oncology Emily.Viehl@luhs.org

Elise Brennan, PharmD Clinical Float

Elise.brennan@luhs.org



# **All Programs Rotation List**

# <u>Clinical and Administrative Rotations</u> (R=Required; E=elective; N=Not offered)

# Unless otherwise specified, duration is 4-5 weeks \*Denotes different duration

Rotation Title	PGY1	PGY2 CC	PGY2 SOT	PGY2 ID
Acute Care				
Cardiology	R	N	N	N
General Medicine	R	N	N	N
Advanced General Medicine	E	N	N	N
Left Ventricular Assist Device (LVAD) Longitudinal Clinic*	Е	N	N	N
(6 months) Advanced Heart Failure Longitudinal Clinic (6 months)	E	N	N	N
Critical Care				
Burn Intensive Care Unit	R	E	N	E
Advanced Burn Intensive Care Unit	N	Е	N	N
Cardiac Care Unit	R	Е	N	N
Cardiovascular Intensive Care Unit	R	R	E	Е
Advanced Cardiovascular Intensive Care Unit	N	Е	N	N
Intensive Care Unit Float* (2-4 weeks)	N	E	N	N
Medical Intensive Care Unit	R	R	Е	Е
Advanced Medical Intensive Care Unit	N	E	N	N
MacNeal Intensive Care Unit	E	E	N	N
Neurosciences Intensive Care Unit	R	R	N	N
Advanced Neurosciences Intensive Care Unit	N	E	N	N
Surgical-Trauma Intensive Care Unit	R	R	E	Е
Advanced Surgical-Trauma Intensive Care Unit	N	Е	N	N
Emergency Medicine				
Emergency Medicine	R	R	N	Е
Advanced Emergency Medicine	N	Е	N	N
MacNeal Emergency Medicine	E	Е	N	N
Infectious Diseases				
Antimicrobial Stewardship	N	N	N	R
Advanced Antimicrobial Stewardship	N	N	N	R
Community Hospital Infectious Diseases	N	N	N	Е
Infectious Diseases	R	R and E*	N	N
General Infectious Diseases Consults	N	N	N	R
Advanced General Infectious Diseases Consults Outpatient Parenteral Antimicrobial Therapy (OPAT)	N	N	N	R
(Longitudinal)* (6 months)	N	N	N	R
Pediatric Infectious Diseases	N	N	N	Е
Transplant Infectious Diseases	R	N	R	R
Advanced Transplant Infectious Diseases	N	N	Ν	Е



0	n	C	o	lo	g	У

Bone Marrow Transplant	R	N	N	N
Hematology/Oncology	R	N	N	Е
Pediatrics				
General Pediatrics/Pediatric Intensive Care Unit	R	N	N	N
Neonatal Intensive Care Unit	R	E	N	N
Pediatric Intensive Care Unit	N	E	N	N
Transplant				
Abdominal Transplant	R	N	R	Е
Advanced Abdominal Transplant - Inpatient	N	N	E	N
Abdominal Transplant Elective – Inpatient	N	N	E	N
Abdominal Transplant - Outpatient	N	N	R	N
Advanced Abdominal Transplant - Outpatient	N	N	E	N
Abdominal Transplant Elective – Outpatient	N	N	E	N
Heart Transplant/Advanced Heart Failure	R	E	R	Е
Heart Transplant/Advanced Heart Failure II	N	N	E	N
Advanced Heart Failure/Cardiac Transplant/ Lung Transplant Clinic	N	N	Е	N
Hepatology	R	N	R	N
Lung Transplant	R	Е	R	E
Advanced Lung Transplant	N	N	Е	N
Pediatric Transplant* (2-4 weeks)	N	N	E	N
Transplant Nephrology	N	N	E	N
Other / Non-Direct Patient Care				
Infection Prevention and Control* (2 weeks)	N	N	N	E
Medication Safety	E	N	N	N
Microbiology* (2 weeks)	N	N	N	R
Nutrition* (2 weeks)	N	E	N	N
Orientation* (duration is program specific)	R	R	R	R
Pharmacy Administration	R	N	N	Ν
Pharmacy Informatics	E	N	N	N
Poison Center/Toxicology	E	E	N	N

Abbreviations: PGY1, PGY1 Pharmacy Residency Program; PGY2 CC, PGY2 Critical Care Pharmacy Residency Program; PGY2 ID, PGY2 Infectious Diseases Pharmacy Residency Program; PGY2 SOT, PGY2 Solid Organ Transplant Pharmacy Residency Program



# **Longitudinal Experiences**

(R=Required; E=elective; N=Not offered)

Experience title	Description	PGY1	PGY2 CC	PGY2 SOT	PGY2 ID
	Pharmacy residents will participate in Emergency Department (ED) Coverage on Monday through Friday evenings (1700-2200). The goal of this shift is to provide additional clinical coverage to the Emergency Department while allowing the resident to practice with an increased amount of autonomy.				
ED On Call* (12 months)	Responsibilities during evening ED clinical shifts     Respond to code and stroke pages throughout the hospital     Attend medical emergencies within the ED     Answer drug information questions and provide recommendations as needed     Complete new start warfarin and vancomycin consults     Perform medication reconciliation as time permits     Other duties as assigned by the evening clinical pharmacists (PM ICU or PM Gen Med)     Pick up code and stroke pagers from daytime resident at 4pm     Pharmacy residents are required to attend a weekly or twice weekly ED coverage on call meeting to discuss cases and receive feedback on case management	R	R	N	N
	Program Learning Experience:  PGY1: Evaluated under Pharmacy Operations (Longitudinal)  PGY2 CC: Evaluated under Emergency Response (Longitudinal)  Pharmacy residents are expected to attend all "Code Blue" emergencies throughout the hospital during regular working hours under the supervision of a preceptor when the resident is on a critical care rotation and/or when the resident is assigned to respond. The pharmacy resident will serve as the primary critical care pharmacist, with preceptor supervision, for adult medical emergencies.  Pharmacy residents will be expected to complete BLS and ACLS certification within the first month of residency.				
Code Blue Response* (12 months)	Expectations: Assist Code Blue team in obtaining necessary medications from the crash cart, Pyxis, and/or central pharmacy Make intravenous drips from the crash cart when needed Assist Code Blue team with therapeutic interventions, including drug and dose recommendations	R	R	N	N
	Program Learning Experience:				
Code Stroke Response* (12 months)	<ul> <li>pager. See the LED for more details on time and expectations</li> <li>PGY1: Evaluated under Pharmacy Operations         (Longitudinal)</li> <li>PGY2 CC: Evaluated under Emergency Response         (Longitudinal)</li> </ul>	R	R	N	N
Pharmacy Operational Staffing* (Longitudinal) (12 months)	The PGY1 pharmacy resident will participate in a regular central pharmacy staffing rotation every third weekend. Activities will include order verification, checking filled medications prior to dispensing, reviewing Pyxis medication fills, preparation of crash cart trays and stroke kits, etc. In addition, residents will respond to code strokes and code blues during their staffing shifts.	R	N	N	N



Program Learning Experience:

 PGY1: Evaluated under Pharmacy Operations (Longitudinal)

The PGY2 pharmacy resident will participate in a specialized clinical shift every third weekend.

PGY2 CC will staff either AM PIC or a clinical shift and will serve as back up to the PGY1 attending medical emergencies within the hospital.

PGY2 SOT will only staff clinical shifts. Refer to "Staffing responsibilities" for more detail.

Pharmacy Clinical Staffing\* (Longitudinal) (12 months)

Participation in

Recruitment

Activities

PGY2 ID will staff either AM PIC or a clinical shift.

#### Program Learning Experience:

 PGY2 CC: Evaluated under Pharmacy Operations (Longitudinal)

Pharmacy residents will be required to actively participate in

 PGY2 ID: Evaluated under Pharmacy Clinical Staffing (Longitudinal) R

R

R

R

Ν

R

R

R

R

R

R

 PGY2 SOT: Evaluated Under Pharmacy Clinical Staffing (Longitudinal)

recruitment efforts of the program because they are an excellent source of information and advice for potential candidates. Current pharmacy residents will be allotted time to meet with perspective pharmacy residents during the interview process. In addition, current pharmacy residents will be expected to provide information to interested parties during the ICHP Residency Showcase and the ASHP Midyear Clinical Meeting Residency Showcase and during other LUMC functions (i.e. job fairs, showcases, etc.). Weekly meetings for PGY2 programs within their specialty. PGY2 residents will be expected to present topics, case presentations, journal clubs, or education in another format. See PGY2 specialty appendices or LEDs for additional information. PGY1s on either critical care, infectious diseases, or solid organ transplant rotations

Specialty Conference

#### Program Learning Experience:

 PGY2 CC: Evaluated under Critical Care Conference (Longitudinal)

are also expected to attend the respective conference.

- PGY2 ID: Evaluated under ID Conference (Longitudinal)
- PGY2 SOT: Evaluated under Solid Organ Transplant (SOT) Conference (Longitudinal)

Abbreviations: PGY1, PGY1 Pharmacy Residency Program; PGY2 CC, PGY2 Critical Care Pharmacy Residency Program; PGY2 ID, PGY2 Infectious Diseases Pharmacy Residency Program; PGY2 SOT, PGY2 Solid Organ Transplant Pharmacy Residency Program

#### Required Residency Projects/Responsibilities

(R=Required; E=elective; N=Not offered)

Project title *denotes longitudinal	Description	PGY1	PGY2 CC	PGY2 SOT	PGY2 ID
Research Project (Longitudinal) (12 months)	Twelve-month experience that all pharmacy residents are required to complete one project designed either to improve the services or function of the pharmacy department or to achieve a specific research objective prior to completion of the pharmacy residency. Each pharmacy resident will have a research advisor for the duration of their research project. Failure to meet deadlines may	R	R	R	R



result in disciplinary action including but not limited to academic probation and/or additional project/presentation assignments as determined by the respective RAC and the RPD.

#### Requirements for completion

- All deadlines and assignments as designated by the Resident Research Committee. See separate documents for recommended timelines.
- Attend Monthly Resident Research Committee Meetings
- Write and present one research pearl during the Research committee meeting
- Design and complete one research project
- Submit a manuscript suitable for publication
- Present project at Pharmacy Resident Research Conference (Spring) or to a professional meeting upon completion (during or at the end of residency)

#### Program Learning Experience:

- PGY1: Evaluated under Research Project (Longitudinal)
- PGY2 CC: Evaluated under Research Project (Longitudinal)
- PGY2 ID: Evaluated under Research Project (Longitudinal)
- PGY2 SOT: Evaluated under Research Project (Longitudinal)

Each pharmacy resident will be required to prepare and present one ACPE (American Council on Pharmacy Education)-accredited continuing education seminar during the pharmacy residency program. Pharmacy residents will select their seminar topic with the guidance of a seminar preceptor (chosen by the resident). Topics should include therapeutic or clinical practice controversies or updates. The goal of the seminar is to develop the pharmacy resident's communication skills, literature evaluation skills, and presentation techniques. The pharmacy resident will also be responsible for creating a self-assessment for audience ACPEaccredited CE credit.

#### Objectives:

- Improvement of presentation and communication skills
- Enhancement of critical thinking skills, particularly involving literature evaluation and ability to respond to audience questions
- Provision of continuing education to pharmacists
- Development of ability to accept constructive criticism and/or comments

See Education Committee Guidance Appendix for additional details

#### Program Learning Experience:

- PGY1: Evaluated under Grand Rounds (Longitudinal)
- PGY2 CC: Evaluated under Continuing Education Seminar (Longitudinal)
- PGY2 ID: Evaluated under Continuing Education Seminar (Longitudinal)
- PGY2 SOT: Evaluated under Continuing Education Seminar (Longitudinal)

All pharmacy residents are required to complete one project designed either to improve the services or function of the Medication Use pharmacy department or to achieve a specific medication use evaluation (MUE) objective prior to completion of the pharmacy residency. Each pharmacy resident will have an MUE advisor for (12 months) the duration of their MUE project. Failure to meet deadlines may result in disciplinary action including but not limited to academic

R R R R

R

R

R

R

Evaluation (Longitudinal)

CE

Presentation

(Longitudinal)

(6 months)



probation and/or additional project/presentation assignments as determined by the respective RAC and the RPD. Requirements for completion

- All deadlines and assignments as designated by the Resident Research Committee. See separate documents for recommended timelines.
- Attend Monthly Research/MUE Committee Meetings
- Design and complete one MUE project
- Present project at Resident Poster Session at ASHP Midyear Clinical Meeting and/or Midyear Vizient poster session (Winter)
- Submit written report of MUE as determined by the MUE preceptor to be presented to Pharmacy and Therapeutics Committee and/or another appropriate LUMC medical staff or quality committee (during or at the end of residency)

Based on findings and conclusions from MUE, initiate and / or complete action items for process improvement as outlined

#### Program Learning Experience:

- PGY1: Evaluated under Medication Use Evaluation (Longitudinal)
- PGY2 CC: Evaluated under Medication Use Evaluation (Longitudinal)
- PGY2 ID: Evaluated under Medication Use Evaluation (Longitudinal)
- PGY2 SOT: Evaluated under Practice Management/Pharmacy Improvement (Longitudinal)

Involvement in pharmacy and hospital committees is an important part of active clinical practice and is highly encouraged. Each pharmacy resident will be assigned to a committee for the duration of the residency year. Pharmacy residents are expected to attend pertinent committee meetings with preceptors whenever possible as a part of regular rotation activities. Required committee activities for a given rotation will be determined at the discretion of the individual preceptor. The PGY2 transplant resident will be given the opportunity to attend and participate in the multidisciplinary review board (MRB) meetings and Quality Assessment Process Improvement (QAPI) meetings for the respective transplant specialty while on rotation. Pharmacy residents may present one MUE and/or one drug monograph (PGY1 and PGY2 if applicable during their year) to the P&T Committee. Available committees include Pharmacy Informatics Committee, Unit Quality Improvement Committees, Medication Safety Committee, Sepsis Committee, P&T Subcommittees, etc.

Committee Responsibilities (12 months)

Program Learning Experience:

Department Research Committee meetings.

 PGY1: Evaluated under Pharmacy Improvement (Longitudinal Committee)

Pharmacy residents are required to attend monthly Pharmacy

- PGY2 CC: Evaluated under Pharmacy Improvement (Longitudinal)
- PGY2 ID: Evaluated under Stewardship Administration (Longitudinal)
- PGY2 SOT: Évaluated under Pharmacy Management/ Pharmacy Improvement

PGY2 residents will be required to complete a writing project, which may include a case report, review article, etc. Objectives:

Writing Project (6 months)

 Improvement of writing skills and identification of appropriate journal selection and requirements E R R

R

R

R

R



- Enhancement of critical thinking skills, particularly involving literature evaluation, clinical application, and ability to summarize clinical relevance
- Development of ability to accept constructive criticism and/or comments and collaborate with other team members

PGY1 residents may pursue an additional writing project if they wish as long as this additional responsibility is communicated to and approved by the RPD.

#### Program Learning Experience:

- PGY1: On demand feedback if needed
- PGY2 CC: Evaluated under Pharmacy Improvement (Longitudinal)
- PGY2 ID: Evaluated under Writing Project (Longitudinal)
- PGY2 SOT: Evaluated under Pharmacy Management/ Pharmacy Improvement

The PGY1 and PGY2 resident will participate in many areas of

pharmacy practice management and improvement including taking action on results from a medication utilization evaluation (MUE), regulatory compliance, hospital committee participation, medical staff education (i.e. physician, nursing, pharmacy in-services), and policy/guideline revision or development. Pharmacy residents will be required to have ongoing participation in a hospital committee. Additionally, PGY2 residents may be required to complete a drug monograph as applicable to the specialty practice. The practice management requirement is flexible to allow for projects to occur organically during the year, but this project will be in addition to the other required projects (i.e. completing an MUE does not complete the practice management

Practice
Management/
Pharmacy
Improvement

Program Learning Experience:

requirement).

- PGY2 CC: Evaluated under Pharmacy Improvement (Longitudinal)
- PGY2 ID: Evaluated under Stewardship Administration (Longitudinal)
- PGY2 SOT: Evaluated under Practice
   Management/Pharmacy Improvement (Longitudinal)

See the Teaching and Learning Certificate Syllabus for details about the program.

The Teaching and Learning Certificate program offered through LUMC for pharmacy residents is an application-based program that prepares pharmacists to become effective teachers. Effective teaching extends beyond residency training and impacts numerous disciplines. Through an interactive environment, the participant will be introduced to the skills needed to grow as an educator and advance the profession of pharmacy.

Teaching and Learning Certificate (Longitudinal) (6 months)

All PGY1 residents and any PGY2 residents who have not already completed a Teaching and Learning Certificate are required to participate in the LUMC Teaching and Learning Certificate Program. PGY2 residents who have completed a Teaching and Learning Certificate will be expected to participate as a preceptor in the Teaching and Learning Certificate curriculum.

Program Learning Experience:

- PGY1: Evaluated under Teaching and Learning Certificate (Longitudinal)
- PGY2 CC: Evaluated under Teaching and Learning Certificate (Longitudinal)
- PGY2 ID: Evaluated under Teaching and Learning Certificate (Longitudinal)

R R/N R/N R/N

R

R

R

R



PGY2 SOT: Evaluated under Teaching and Learning Certificate (Longitudinal)

The pharmacy resident will gain experience by giving various types of presentations throughout the year to a variety of healthcare professionals, including pharmacists, physicians, and nurses. The goal of these presentations is to enhance the

Required, as needed

Additional Presentations and Projects

resident's presentation, communication, and teaching skills as both a clinician and an educator. Completion of required presentations will be monitored by the pharmacy resident and pharmacy resident presentation preceptor. Residents may be asked to repeat presentations or to complete additional projects/presentations. This will be determined at the discretion of the respective RAC and the RPD.

Abbreviations: PGY1, PGY1 Pharmacy Residency Program; PGY2 CC, PGY2 Critical Care Pharmacy Residency Program; PGY2 ID, PGY2 Infectious Diseases Pharmacy Residency Program; PGY2 SOT, PGY2 Solid Organ Transplant Pharmacy Residency Program



#### **Staffing Responsibilities and Requirements**

- I. Pharmacy residents will be exempt from staffing on the following weekends:
  - a. ASHP Midyear Clinical Meeting (December)
  - b. If other weekends are required for travel to a meeting or other residency related activity, finding coverage for the assigned shifts that weekend is the responsibility of the resident.

#### II. PGY1 Residents

- a. The goal of the longitudinal pharmacy operations experience is to ensure that the pharmacy resident is able to function independently as a pharmacist both from a clinical and operational perspective. As a PGY1 resident, staffing focuses primarily on the operational aspect.
- b. The PGY1 pharmacy resident will be required to work two 8-hour shifts every 3rd weekend on the AM counter shift (0630-1500), mid counter shift (1030-1900), or counter PM shift (1230-2100).
- c. PGY1 pharmacy residents will be required to work a minimum of three LUMC holidays each.
- d. PGY1 residents may be required to staff up to an additional 10 shifts per year to support the operational needs of the pharmacy department.
- e. Responsibilities during staffing shifts (refer to training materials provided during orientation for a complete list)
  - i. Order verification for the whole hospital
  - ii. Medication checking and dispensing
  - iii. Antimicrobial stewardship of restricted antimicrobials
  - iv. Answering drug information questions
  - v. Emergency response to stroke codes in the hospital and ED
  - vi. Emergency response to code blues in the hospital
  - vii. Additional roles as needed

#### III. PGY2 Critical Care Residents

- a. The goal of the longitudinal pharmacy operations experience is to ensure that the pharmacy resident is able to function independently as a pharmacist both from a clinical and operational perspective.
- b. The PGY2 pharmacy resident will be required to work two 8-hour shifts every 3<sup>rd</sup> weekend on the AM PIC shift (0630-1500), clinical shift (0730-1600), or another shift as departmental needs dictate.
- c. Holidays: PGY2 pharmacy residents will be required to work a minimum of two LUMC holidays each.
- d. PGY2 Residents may be required to staff up to an additional 10 shifts per year to support the operational needs of the pharmacy department.
- e. Responsibilities during AM PIC staffing shifts (refer to training materials provided during orientation for a complete list)
  - i. Order verification for the whole hospital
  - ii. Medication checking and dispensing
  - iii. Borrowing, lending medications if appropriate
  - iv. Additional roles as needed
- f. Responsibilities during clinical staffing shifts (refer to training materials provided during orientation for a complete list)
  - i. Pharmacokinetics consults assigned units
  - ii. Anticoagulation consults assigned units



- iii. Review of renal dosing list assigned units
- iv. Double check of TPNs in CAPS and EPIC
- v. Follow-up on all clinical sign outs from service clinicians
- vi. Documentation of interventions in the I-Vent system
- vii. Dispensing of parenteral prostacyclins as needed based on sign outs from service clinicians
- viii. Order verification as needed for assigned inpatient units
- ix. Additional roles as needed

#### IV. PGY2 SOT Residents

- a. The goal of the longitudinal pharmacy operations experience is to ensure that the pharmacy resident is able to function independently as a pharmacist both from a clinical and operational perspective.
- b. The PGY2 pharmacy resident will be required to work two 8-hour shifts every 3<sup>rd</sup> weekend on one of the clinical shifts (0730-1600).
- c. Holidays: PGY2 pharmacy residents will be required to work a minimum of two LUMC holidays each.
- d. PGY2 Residents may be required to staff up to an additional 10 shifts per year to support the operational needs of the pharmacy department.
- e. Responsibilities during clinical staffing shifts (refer to training materials provided during orientation for a complete list)
  - i. Order verification as needed for assigned inpatient units
  - ii. Pharmacokinetics consults assigned units
  - iii. Anticoagulation consults assigned units
  - iv. Review of renal dosing lists assigned units
  - v. Double check of TPNs in CAPS and EPIC
  - vi. Follow-up on all clinical sign outs from service clinicians
  - vii. Documentation of interventions in the I-Vent system
  - viii. Dispensing of parenteral prostacyclins as needed based on sign outs from service clinicians
  - ix. Follow-up on immunosuppression therapeutic drug monitoring for assigned services
  - x. Additional roles as needed

#### V. PGY2 Infectious Diseases Residents

- a. The goal of the longitudinal pharmacy operations experience is to ensure that the pharmacy resident is able to function independently as a pharmacist both from a clinical and operational perspective.
- b. The PGY2 pharmacy resident will be required to work two 8-hour shifts every 3<sup>rd</sup> weekend on the AM PIC shift (0630-1500), clinical shift (0730-1600), or another shift as departmental needs dictate.
- c. Holidays: PGY2 pharmacy residents will be required to work a minimum of two LUMC holidays each.
- d. PGY2 Residents may be required to staff up to an additional 10 shifts per year to support the operational needs of the pharmacy department.
- e. Responsibilities during AM PIC staffing shifts (refer to training materials provided during orientation for a complete list)
  - i. Order verification for the whole hospital
  - ii. Medication checking and dispensing
  - iii. Borrowing, lending medications if appropriate
  - iv. Additional roles as needed



- f. Responsibilities during clinical staffing shifts (refer to training materials provided during orientation for a complete list)
  - i. Pharmacokinetics consults assigned units
  - ii. Anticoagulation consults assigned units
  - iii. Review of renal dosing list assigned units
  - iv. Double check of TPNs in CAPS and EPIC
  - v. Follow-up on all clinical sign outs from service clinicians
  - vi. Documentation of interventions in the I-Vent system
  - vii. Dispensing of parenteral prostacyclins as needed based on sign outs from service clinicians
  - viii. Order verification as needed for assigned inpatient units
  - ix. Additional roles as needed



#### **Evaluation Procedures**

All evaluations for both residents and preceptors are due within 5 business days of completing the learning experience.

During the first month of the pharmacy residency, each pharmacy resident will meet with the RPD to discuss Goals and Objectives and the pharmacy resident's individual goals. They will develop a customized curriculum of learning experie nces and projects to help achieve these goals throughout the year.

#### **Evaluation Definitions**

- Achieved for the Residency (ACHR): The resident has consistently demonstrated the ability to accomplish the educational goal or objective with little or no instruction. Resident requires facilitation but requires minimal coaching. No further evaluation is required.
- Achieved (ACH): The resident has consistently demonstrated the ability to accomplish the
  educational goal or objective with minimal instruction. The resident may require some
  coaching; however, they have progressed to the point that preceptor is able to largely
  facilitate the resident's learning experience with occasional coaching and no modeling.
- Satisfactory progress (SP): The resident has progressed at the required rate to attain full
  ability to perform the educational goal or objective by the end of the program. The resident
  demonstrates the ability to adjust performance based on feedback. The resident requires
  coaching and modeling but is able to work somewhat independently. The preceptor is
  required to provide specific, actionable feedback on what actions the resident must
  consistently do to reach "achieved".
- Needs improvement (NI): The resident's level of skill on the educational goal or objective
  does not meet the preceptors' standards of "achieved" or "satisfactory progress" due to
  failure to incorporate feedback and improve performance or inability to assess performance
  due to lack of rotation participation or attendance. The resident requires significant
  modeling and coaching and is not able to perform independently. The preceptor is required
  to provide specific, actionable feedback or a feedback action plan on what actions the
  resident must consistently do to reach "satisfactory progress".

#### **Preceptor and Rotation Evaluations**

Each pharmacy resident will complete a summative evaluation of both the preceptor and the overall learning experience at the end of each learning experience. Evaluations will be completed via PharmAcademic. Residents are required to submit a minimum of one specific suggestion for improvement for each rotation. These suggestions will be used to develop a yearly preceptor development curriculum.

#### **Rotation Performance Evaluation**

Each preceptor will complete a summative evaluation of each pharmacy resident at the end of each learning experience. Evaluations will be completed via PharmAcademic. Preceptors will also complete a less formal (verbal or written) mid-point evaluation of each pharmacy resident. See evaluation definitions above for required documentation according to the evaluation designation. Preceptors must comment on at least 6 objectives per evaluation. Preceptors will review their evaluation with the resident, all feedback provided in the PharmAcademic evaluation should be discussed or provided prior to PharmAcademic submission.



Residents who receive "needs improvement" on the same objective more than once (consecutive or non-consecutive) or who receive two or more "needs improvement" during any one rotation may prompt further review by the RPD to determine if a more structured or formal action plan needs to be put in place. Other performance-related concerns identified by the preceptor(s) and/or RPD may also prompt similar review by the RPD and will be discussed proactively with the resident.

#### **Self-Evaluation**

Each pharmacy resident will complete a summative self-evaluation at the end of a learning experience as assigned by the LED/preceptor, commenting on at least two strengths and two areas for improvement for the rotation Evaluations will be completed via PharmAcademic.

#### **Quarterly Development Meetings**

Pharmacy residents will be evaluated by the RPD on a quarterly basis. Progress toward achieving the criteria-based residency program goals and objectives, individual goals established at the beginning of the residency, and overall residency performance will be evaluated.

The RPD takes into consideration the evaluations from preceptors, the pharmacy resident's self-evaluations, and other pertinent information to complete an assessment of the pharmacy resident's progress using the criteria-based goals and objectives and will then add his/her assessment of the pharmacy resident's progress to the customized plan in PharmAcademic. On completion, the RPD and resident will meet to discuss progress, plans for the next quarter and both will then sign off on the customized plan.

For PGY1 residents, their mentor will also attend quarterly development meetings. For PGY2 residents, the residency coordinator may attend quarterly development meetings as able.



# **Pharmacy Residency Certificate**

A pharmacy residency certificate will be awarded upon successful completion of all pharmacy residency requirements. Complete lists of requirements are in each program-specific appendix. All training requirements must be met prior to the end of the residency period.


- It is possible to obtain a limited extension for completion of the research project. If an extension is needed, the resident must request such an extension in writing a minimum of 60 days prior to the end of the pharmacy residency.
- Such requests will be evaluated on a case-by-case basis by the RPD.
- The RPD and the research preceptor must approve all such requests before an extension may be granted.
- Extensions will be limited to a six-month period after completion of the pharmacy residency; and the pharmacy residency certificate will be withheld until **ALL** requirements, including the research project, have been successfully completed.

#### Criteria for Graduation\*

\*PGY2 criteria for graduation is program specific and is in each of the PGY2 appendices.

- ✓ Obtain licensure by the required date
- ✓ Complete all assigned PharmAcademic evaluations and customized plan updates
- ✓ Upload all final presentations and projects listed below to PharmAcademic Files
  - Final MUE Poster
    - PGY1: Objective R2.1.2
  - Final MUE Write Up (if required by MUE preceptor) and presentation at P&T and/or other committees as determined by the project
    - PGY1: Objective R2.1.6
  - Final Research Project Manuscript (deemed publishable by research preceptors) and Residency Research Conference presentation
    - PGY1: Objectives R2.1.5, R2.1.6
  - o Final CE Seminar Presentation
    - PGY1: Objectives R4.1.1, R4.1.2, R4.1.4
  - o Final Teaching Certificate Portfolio
    - PGY1: Objectives R4.1.1, R4.1.2, R4.1.3, R4.1.4
  - Final Journal Club and Case Presentation PowerPoints (PGY1s only)
  - Additional projects as applicable (i.e. monographs, in-services, guideline/order set/protocol revisions, etc.)
    - PGY1: Objectives R1.4.2, R2.1.1
- ✓ Receipt of ≥ 75% "Achieved for the Residency" for all program objectives on final residency evaluation
  - Receipt of a minimum of "Satisfactory Progress" on all objectives not marked as "Achieved for the Residency"
- ✓ The final program quarterly development plan is submitted by the RPD.
- ✓ All PharmAcademic evaluations are completed by the preceptors and residents.
- ✓ Satisfactory completion of all rotations as determined by the primary preceptor for each rotation
- ✓ Completion of the Teaching and Learning Certificate Program as applicable
- ✓ Completion of weekend staffing shifts (minimum 10 weekends, equivalent to ~160 hours)
- ✓ Completion of all assigned residency projects as determined by the RPD and described elsewhere in this manual.







# **Residency Position Descriptions and Responsibilities**

#### I. All programs

- A. Residency Program Director (RPD)
  - i. Each pharmacy residency training program has a qualified RPD according to the standards set by ASHP who is responsible for the overall quality of the pharmacy residency training program. The RPD is responsible not only for precepting pharmacy residents, but also for the evaluation and development of all other preceptors in the pharmacy residency program.
  - ii. Activities of the RPD include recruitment of applicants, selection of applicants, maintaining and updating the pharmacy residency rotation standards, and monitoring of pharmacy resident progress.
  - iii. The RPD is responsible for maintaining the pharmacy residents' and preceptors' permanent files.
  - iv. The RPD is the Chair of the Residency Advisory Committee (RAC) and leads that group at meetings and coordinates all the decisions made by the RAC as pertains to the residency program.
- B. Residency Program Coordinator (RPC)
  - Each pharmacy residency program may have at least one residency program coordinator to assist the RPD with the development of both residents and other preceptors.
- C. Pharmacy Residency Preceptor
  - i. Refer to Pharmacy Residency Preceptor and Preceptor Development Policy
    - 1. Reappointment of qualified preceptors
      - a. Appointed preceptors will be formally re-evaluated at least every two years via ASHP APR forms
        - Applications will undergo the same review as the initial appointment
    - 2. Preceptor Development
      - a. Process for preceptor development
        - i. Educational opportunities for preceptors to improvement their precepting skills will be offered throughout the year
        - ii. Focused plans will be implemented if any specific areas of need are identified
        - iii. At least three to four opportunities will be available per residency year through Pharmacy Grand Rounds
          - Primary preceptors must attend a minimum of two sessions per residency year. All preceptors are encouraged to attend as many sessions as they are available. Attendance will be recorded and monitored.
- D. Pharmacy Residents
  - i. Qualifications of the Pharmacy Residency Applicant
    - Pharmacy residency applicant qualifications will be evaluated by the Pharmacy Residency Program Director through an established formal procedure.



- 2. The applicant should be a graduate of an Accreditation Council for Pharmacy Education (ACPE)-accredited Doctor of Pharmacy degree program.
- 3. Applicants who have graduated from an ACPE-accredited Bachelor of Science (B.S.) in pharmacy degree program may also be considered.
- 4. The applicant must be licensed or eligible for licensure in the State of Illinois
- 5. If licensure is not obtained prior to entering the residency program, it must be obtained within 120 days from the start of residency.
- 6. Applicants must participate in and adhere to the rules of the Resident Matching Program (RMP) process.
- ii. PGY2 applicants must adhere to the above qualification and additionally should be a graduate of an ASHP-accredited or ASHP candidate accreditation status PGY1 Residency Program.
- iii. Obligations of the Pharmacy Resident to the Pharmacy Residency Program
  - 1. Pharmacy residents' primary professional commitment must be to the residency program.
  - 2. Pharmacy Residents must manage external activities so as not to interfere with the program.
  - 3. Pharmacy residents are responsible for making any changes necessary to meet the requirements for successful completion of the pharmacy residency.
  - 4. Pharmacy residents must be committed to the values and mission of LUMC.
  - 5. Pharmacy residents must be committed to completing the educational goals and objectives established.
  - 6. Pharmacy residents must seek constructive verbal and documented feedback that directs their learning.
  - 7. Pharmacy residents must be committed to making active use of the constructive feedback provided by Pharmacy Residency Preceptors.

# II. PGY1 Only

#### A. Resident Mentor

- i. During the first month of the pharmacy residency program, each pharmacy resident will choose a mentor.
- ii. This person must be one of the Pharmacy Residency Preceptors and/or a member of the Pharmacy Residency Advisory Committee and will serve as the pharmacy resident's "go to" person for any issues or concerns that may arise during the residency year.
- iii. The mentor will serve as a resource and advocate for professional development.
- iv. The pharmacy resident will have a formal meeting with their mentor and RPD on a quarterly basis and may meet more frequently if warranted or desired.
- v. Prior to this quarterly meeting, the pharmacy resident should complete a quarterly self-evaluation that will be discussed with the mentor. See "Evaluation Procedures-Quarterly Progress Meeting" for details.
- vi. The mentor will report to the RAC regarding the pharmacy resident's progress during RAC meetings.
- vii. The goals of the relationship between the pharmacy resident and the Pharmacy Resident Mentor are:



- Give the pharmacy resident a contact person who will be available for questions and/or concerns, who can assist the pharmacy resident with overall planning for the year, help the pharmacy resident with problemsolving, support the overall wellbeing of the resident, and serve as a sounding board and advisor to the pharmacy resident as they prepare for their future career.
- 2. Give all preceptors a contact person with whom they can discuss the pharmacy resident's progress, and who can then report to the RPD and track the overall progress of the pharmacy resident



### III. Pharmacy Residency Committees

# A. Residency Education Sub-Committee

- i. Purpose:
  - 1. Establishes and oversees resident educational activities, namely the Grand Rounds curriculum and presentation expectations.
  - 2. Ensures all resident presentation instructions, evaluations, and requirements are provided to residents and are followed throughout the year.
  - 3. Tracks resident progress on presentations throughout the year, ensuring adherence to deadlines.
  - 4. Tracks preceptor evaluations of resident presentations and ensures residents receive timely feedback.
- ii. The Residency Education Sub-Committee is led by two co-chairs, whose responsibilities include, but are not limited to, leading committee meetings, creating meeting agenda and minutes, ensuring the committee performs its duties, and reporting activities to PGY1 RAC, PGY2 CC RAC, PGY2 SOT RAC, and/or PGY2 ID RAC as appropriate.
- iii. The Teaching Certificate Coordinator is a member of the Residency Education Sub-Committee
  - The Teaching Certificate Coordinator is responsible for developing and maintaining a curriculum and a syllabus for the teaching certificate program.
  - 2. The coordinator is responsible for organizing seminars and lectures for the program as well as coordinating teaching opportunities for the residents including precepting and lecturing opportunities.

# B. Residency Professional Development and Wellness Sub-Committee

- i. Purpose:
  - 1. Organize professional/preceptor development and wellness sessions for residents and/or residency preceptors throughout the year.
  - 2. Assists in PGY-1 recruitment activities, including, and not limited to, organization of recruitment events, assistance with residency interviews, and helping the PGY-1 RPD in the management of the LUMC Pharmacy Residency X and Instagram account.
- ii. The Residency Professional Development and Wellness Sub-Committee is led by two co-chairs, whose responsibilities include, but are not limited to, leading committee meetings, creating meeting agenda and minutes, ensuring the committee performs its duties, and reporting activities to PGY-1 RAC, PGY-2 CC RAC, PGY-2 SOT RAC, and/or PGY-2 ID RAC as appropriate.

# C. Residency Research & MUE Sub-Committee

- i. Purpose:
  - 1. Organize monthly resident research meeting curriculum (i.e. resident led topic discussions such as REDCap, SPSS, poster development, manuscript writing, etc.)
  - 2. Tracks resident research and MUE projects monthly and ensures appropriate progress is being made throughout the year in conjunction with research project preceptors.



- Oversees appropriate resident submissions to national conferences, such as ASHP Midyear Clinical Meeting, Vizient, and Residency Research Conference.
- Coordinates preceptor research and MUE project proposal list prior to the start of each new residency class and appropriately vets each project via criteria that the committee sets for a feasible resident project
- ii. The Residency Research and MUE Sub-Committee is led by two co-chairs, whose responsibilities include, but are not limited to, leading committee meetings, creating meeting agenda and minutes, ensuring the committee performs its duties, serving as mentors for both pharmacy residents and preceptors for the research project, working with the research committee and RPDs to determine the feasibility and relevance of proposed projects, developing a timeline for submission of project components (including IRB protocol, posters, presentations, and the manuscript), overseeing the IRB submission process and coordinating the submission of the residents' posters to the ASHP Midyear Clinical Meeting poster session and the Pharmacy Resident Research Conference, assisting the RPD with evaluations pertaining to the research project and related presentations and posters, and reporting activities to PGY-1 RAC, PGY-2 CC RAC, PGY-2 SOT RAC, and/or PGY-2 ID RAC as appropriate.

# D. PGY-1 Residency Advisory Committee (RAC)

- The RAC is comprised of the Pharmacy Residency Program Directors, Pharmacy Residency Coordinators, Pharmacy Residency Sub-Committee Chairs, and selected Pharmacy Residency Preceptors from diverse rotation areas.
- ii. The PGY1 RAC meets on a quarterly basis.
- iii. Purpose of the RAC:
  - Overseeing the monthly PGY-1 Preceptor Handoff Meetings by tracking the progress of all PGY-1 pharmacy residents and facilitating communication regarding their progress amongst all of the pharmacy Residency Preceptors
  - 2. Evaluating the pharmacy PGY-1 program at LUMC and making decisions, through discussion and democratic process, regarding program changes and/or adjustments
  - 3. Facilitating preceptor education and training
  - 4. Selection of pharmacy residency program applicants and determination of rank order list
  - 5. Approval of pharmacy residency projects and seminar topics
- iv. All decisions regarding the structure, content, and pharmacy residency goals and objectives of the program are discussed and then recommendations for any changes made by the committee are ultimately approved or denied by the RPD.

# E. PGY-2 Critical Care Residency Advisory Committee (PGY-2 CC RAC)

i. PGY-2 CC RAC is comprised of all the critical care and emergency medicine preceptors. Other preceptors who are precepting a PGY-2 Critical Care Resident will be invited to RAC for the relevant months to discuss resident's progress. Other preceptors may be invited to attend if needed.



ii. Meets on a monthly basis to discuss progress of the resident(s).

# F. PGY-2 Solid Organ Transplant Residency Advisory Committee (PGY-2 SOT RAC)

- i. PGY-2 SOT RAC is comprised of all solid organ transplant preceptors. Other preceptors who are precepting a PGY-2 Solid Organ Transplant Resident will be invited to RAC for the relevant months to discuss resident's progress. Other preceptors may be invited to attend if needed.
- ii. Meets on a monthly basis to discuss progress of the resident(s).

# G. PGY2 Infectious Diseases Residency Advisory Committee (PGY2 ID RAC)

- PGY2 ID RAC is comprised of all infectious diseases preceptors. Other
  preceptors who are precepting the PGY-2 Infectious Diseases Resident will
  be invited to RAC for the relevant months to discuss resident's progress.
  Other preceptors may be invited to attend if needed.
- ii. Meets on a monthly basis to discuss progress of the resident(s).



#### **General Employment Information and Pharmacy Resident Benefits**

- I. Benefits
  - a. Salary
    - i. Paid every two weeks on Friday
    - ii. If a holiday falls on a Friday on which a paycheck is due, employees are paid the business day prior to the holiday.
    - iii. PGY-1 Salary \$53,000
    - iv. PGY-2 Salary \$55,500
  - b. Health Insurance (Medical, Dental, and Vision)
    - All residents holding a valid graduate pharmacy education agreement with Loyola are eligible for health benefits and become covered on the first day of pharmacy residency provided that enrollment takes place within the first 30 days of pharmacy residency.
    - ii. Benefit options are summarized in the benefits package and are described in detail in the individual summary Plan Descriptions.
    - iii. Pharmacy residents must sign up for coverage and complete the necessary enrollment forms.
    - iv. Any change in health plans is permitted only during the open enrollment period or with a qualifying life event. Open enrollment typically occurs during the fall.
    - v. Newly eligible dependents may be added within 30 days of marriage, birth or adoption, or loss of current coverage. Otherwise, such additions may only be made during the open enrollment period. Rates are subject to change.
  - c. Time away from the program (ASHP standard limit 37 days):
    - i. Paid Time Off (PTO): 16 days
      - 1. PTO is to include vacation, personal, and sick days
    - ii. Educational Days: 10 days
      - Up to 3-4 educational days for travel to the ASHP Midyear Clinical Meeting
      - Up to 2 educational days for travel to the designated Pharmacy Residency Research Conference (PGY1, PGY2 CC, PGY2 SOT PGY2 ID)
      - 3. Additional requests for conference time will be addressed on a case-by-case basis
      - 4. Up to 3 educational days for PGY2 or job interviews. These may be allocated in half-day increments to accommodate half-day interviews at the program director's discretion. Any time off for interviews beyond 3 days will be counted as PTO days.

#### **Attendance and Leave Policies**



- I. All requests for vacation, personal time, and professional leave must be submitted to the RPD and the preceptor for that month for approval.
  - a. Requests must be submitted via email a MINIMUM of 4 weeks in advance.
  - b. Upon approval of the request, the RPD will forward the request to the department's schedule coordinator and administrative assistant.
  - c. A maximum of 5 consecutive vacation days may be used at one time.
  - d. Paid time off is not cumulative from year-to-year. Payment in advance or payment for unused time will not be permitted.
  - e. For the last two weeks of the residency program, PTO will be approved by all RPDs in conjunction with the Regional Director of Clinical Pharmacy Services and Residency Programs. PTO may be limited during this time to ensure department needs are met.

#### II. Absence due to illness

- a. In the case of absence due to illness, the pharmacy resident must notify the preceptor for that month via email, phone, or pager a MINIMUM of 2 hours before the resident would be expected to report to rotation.
- b. Missing a shift due to illness or injury is considered an "unscheduled absence" and will incur one "occurrence" for each instance. One "occurrence" encompasses all consecutive days in one absence period. For example, if the resident is absent for two consecutive days due to the same illness, this is considered one occurrence.
- c. If an absence due to an illness or injury is 3 or more days or when a pattern of absences develops, the resident will be required to submit a physician's statement confirming the reason for the absence.
  - i. If illness is due to COVID-19, the need for a physician's documentation is usually waived due to the requirement for Employee Health to approve return to work after COVID-19 infection. This is subject to change according to current Employee Health guidance.

#### III. Rotation Attendance

- a. Pharmacy residents may be absent (planned or unplanned) from a rotation for a maximum of 25% of the available rotation days.
- b. If a resident is absent from rotation for more than 25% of available rotation days on a given rotation, the pharmacy resident may be required to extend the rotation accordingly or repeat the rotation at the discretion of the RPD.
- IV. Unscheduled Absences/Tardiness: Unscheduled absences, patterns of absence, and tardiness will be managed according to Trinity Health Human Resources Ministry-Wide Policy No. 1035: Attendance.
- V. In the event that a resident must take an extended leave that will go beyond the allotted amount of PTO, they may be eligible to apply for an extended leave of absence. Refer to Trinity Health policy No. 1027 Elective and Other Leaves of Absence, No. 1025 FMLA Military Leave, and No. 1024 FMLA Non-Military Leave for additional details. Every effort will be made to allow the resident to complete the residency by extending the residency completion date in accordance with the amount of leave required. Any extensions to the program will be equivalent in time and competencies. See Appendix 6 for further details.
- VI. In the event that a resident must take a leave greater than 12 weeks, the resident may be released from the program.

#### **Illinois Pharmacist Licensure**



- I. ASHP Standard: A minimum of two-thirds of the residency must be completed as a pharmacist licensed to practice in the program's jurisdiction.
- II. Each pharmacy resident must provide the RPD with the registration number of licensure in all states and/or initiate as early as possible plans for obtaining pharmacist licensure in the State of Illinois.
- III. Each pharmacy resident must obtain and maintain, at their own expense, pharmacy technician licensure in the State of Illinois prior to the start of the residency program if they are not already licensed as a pharmacist in the state of Illinois.
- IV. Each pharmacy resident must obtain and maintain, at their own expense, pharmacy licensure in the State of Illinois prior to or within 120 days after the start of the residency.
  - a. Pharmacy residents must schedule their initial exams prior to July 1<sup>st</sup> of the residency start year and provide scheduled date(s) to the appropriate RPD as soon as exam dates are known.
  - b. If the pharmacy resident is unable to obtain licensure within 120 days from the start of the residency, the pharmacy resident may be dismissed from the pharmacy residency program.
  - c. The pharmacy resident is responsible for discussing the circumstances with the RPD, and an extension may be granted at the discretion of the RPD.
    - i. If an exception is granted, the residency will be extended to ensure 2/3 of the pharmacy training is completed as a licensed pharmacist.
    - ii. A copy of the Illinois License must be forwarded to the RPD as soon as it is available.
  - d. Incoming PGY2 residents must provide a copy of their PGY1 certificate of completion to their RPD within 30 days of the start of the residency. Failure to provide a PGY1 certificate of completion within 30 days of the start of the PGY2 residency will result in dismissal from the residency program and termination of employment. The PGY1 certificate of completion will be uploaded into their PGY2 PharmAcademic™ files tab.

# **Performance Improvement Plans (PIP)**

Residents with ongoing educational and/or clinical deficiencies may be placed on a Performance Improvement Plan (PIP) at the discretion of the RPD and / or Director of Clinical Pharmacy Services and Residency Programs and in consultation with Human Resources. The RPD will provide the resident with the PIP in writing, outlining deficiencies that need to be corrected and the timeline for doing so. Failure to make such corrections may result in further action, up to and including termination from the pharmacy residency program and separation from the organization. Salary and benefits remain in full force during the period that the PIP is in place.

Deficiencies is defined as a resident failing to make progress in any aspect specific to
the residency program completion requirements [e.g. "Needs Improvement" (NI) for the
same objective on more than one summative evaluation, multiple NI's for a single
summative evaluation, regression from "Satisfactory Progress" ((SP) or "Achieved"
(ACH) to NI, not meeting progression expectations during a learning experience, not
meeting deadlines], or if there is a concern with other behaviors related to performance
(e.g., unprofessional behavior, plagiarism).



The RPD shall schedule a meeting with the pharmacy resident to discuss the reason(s) for placement on a PIP, the remedial action(s) required by the pharmacy resident, and the dates for review and/or completion of goal attainment. The RPD shall summarize this meeting in writing to the pharmacy resident. A copy of the written document will be placed in the pharmacy resident's file.

The RPD shall meet with the pharmacy resident weekly to review performance. Depending upon the resident's performance, they may be removed from the PIP, be given an extension of the PIP period, or be terminated from the pharmacy residency program.

Resident complaints related to placement on a PIP can be made by following the chain of command or by contacting the Human Resources Department.

# **Corrective Disciplinary Action**

Whenever the professional activities, conduct or demeanor of a pharmacy resident interferes with the discharge of assigned duties or the discharge of duties of other Loyola employees, or jeopardizes the well-being of patients or employees, Loyola, through its administration, reserves the right to institute appropriate corrective measures including disciplinary action up to and including termination.

The following is a list of pharmacy resident actions and behaviors, which may result in disciplinary action, up to, and including termination for the first offense. This list is not exhaustive and other actions or behaviors may lead to disciplinary action, up to and including termination.

- Behavior that threatens the well-being of patients, medical staff, employees, or the general public.
- Substantial or repetitive conduct that is considered by the pharmacy resident's supervisor
  to be professionally or ethically unacceptable or which is disruptive to the normal and
  orderly function of Loyola.
- Failure to conform to the principles outlined in the Graduate Pharmacy Education Agreement or to the policies and procedures of Loyola.
- Failure to comply with federal, state and local laws (directly or indirectly related to the pharmacy profession.) Convictions for offenses other than minor traffic violations may be cause for dismissal.
- Fraud by commission or omission in application for pharmacy residency position or in completing of other Loyola or patient care related documents.
- Conviction of a criminal offense related to healthcare fraud or exclusion, debarment, sanction or other declaration of ineligibility for participation in a federal or state healthcare program.
- Suspension revocation or any other inactivation, voluntary or involuntary, of pharmacy licensure by the State of Illinois.
- Continued or unexcused absence from duty assignments.
- Harassment or abuse of patients, other residents or hospital staff.
- Failure to provide safe, effective and compassionate patient care commensurate with the resident's level of advancement and responsibility.
- Breach or violation of patient confidentiality



• Conduct or behavior which may cause embarrassment or bring disrepute to Loyola or its employees.

Initiation of disciplinary action shall be the province of the RPD in conjunction with the Regional Director of Clinical Pharmacy Services and Residency Programs when needed and in consultation with Human Resources. Pharmacy residents may be subject to coaching, written warning, suspension or termination. Discipline may be progressive in that it follows the order listed. However, depending upon the severity of an incident or extenuating circumstance, discipline may begin at any stage, including termination.

The RPD may issue a letter of warning (verbal or written) to a pharmacy resident in response to an identified problem. The letter will detail the situation, the action required to correct the problem, and the consequences of failing to correct the problem. A copy of the letter will be placed in the pharmacy resident's file.

Suspension is a corrective action where the pharmacy resident is temporarily removed from program duties. Suspensions are unpaid; however, benefits will remain in full force during the suspension. During the suspension, the pharmacy resident will not receive credit for the training time.

The RPD may initiate a suspension when he/she believes that a pharmacy resident's removal from duty is in the best interest of Loyola or its patients. If necessary, pharmacy residents may be suspended pending the investigation of an incident. Upon conclusion of the investigation, the pharmacy resident may be:

- Restored to full duty (Back pay will be awarded if the results of the investigation establish that suspension was unwarranted.); or
- Terminated.

The RPD shall provide the pharmacy resident with a letter detailing the reason(s) for suspension including the length of the suspension, the action required to correct the reason for the suspension and the consequences of failing to correct the problem. A copy of the correspondence shall be placed in the pharmacy resident's file.

If corrective disciplinary action does not improve a pharmacy resident's behavior or actions or if a major violation of Loyola policy or pharmacy residency policy occurs, the pharmacy resident may be terminated from participation in Loyola's pharmacy residency training program. Termination may occur even if the resident holds a current graduate pharmacy education agreement.

The RPD shall provide a letter to the resident detailing the reason(s) for termination and the effective date. A copy of the correspondence shall be placed in the pharmacy resident's file.

Resident complaints related to formal Corrective Actions may be made as outlined in Trinity Health Human Resources Ministry-Wide Policy No. 1003 – Employee Complaint / Appeal Procedures.



# **Duty Hours**

See Appendix 5: Duty Hours for more details on duty hours and moonlighting

- Duty hours: Defined as all hours spent on scheduled clinical and academic activities, regardless of setting, related to the pharmacy residency program that are required to meet the educational goals and objectives of the program.
  - Outy hours includes: inpatient and outpatient patient care (resident providing care within a facility, a patient's home, or from the resident's home when activities are assigned to be completed virtually); staffing/service commitment; in-house call; administrative duties; work from home activities (i.e., taking calls from home and utilizing electronic health record related to at-home call program); and scheduled and assigned activities, such as committee meetings, classroom time associated with a master's degree for applicable programs or other required teaching activities and health and wellness events that are required to meet the goals and objectives of the residency program.
  - Duty hours excludes reading, studying, and academic preparation time (e.g. presentations, journal clubs, closing knowledge gaps); travel time (e.g., to and from work); and hours that are not scheduled by the residency program director or a preceptor
- Duty hours must be limited to 80 hours per week, averaged over a 4-week period, including all moonlighting. Residents must have a minimum of one day in seven days free of duty, averaged over 4 weeks. Residents must have 8 hours free of duty between scheduled duty hours. Duty periods should not exceed 16 hours.
- Residents will complete a monthly PharmAcademic evaluation to attest to his/her adherence to duty hour requirements.

## Moonlighting

Moonlighting is defined as voluntary, compensated, work performed outside the
organization (external) or within the organization (internal) or at any of the residency's
related participating sites. These are compensated hours beyond the residents' salary
and are not part of the scheduled duty periods of the residency program.

# **Travel Expenses Policy**

Any changes to the below would be in accordance with the Trinity Health Travel and Other Business Expenses Finance Procedure No. F.1

Pharmacy residents will follow the general Trinity Health Travel Expenses Procedure. Each pharmacy resident will receive a \$1500 allotment to fund registration and travel to the ASHP Midyear Clinical Meeting. The pharmacy resident's allotment will be used to pay for registration, airfare, hotel room, and meals for the conference. Expenses will be reimbursed by the Pharmacy Department up to the maximum of \$1500.

Travel expenses to the designated Pharmacy Residency Research Conference (including registration, fuel, hotel, and meals) will be reimbursed by the Pharmacy Department (up to a maximum of \$800).



Travel expenses to the American Transplant Congress including registration, airfare, hotel room, and meals for the conference will be reimbursed by the Pharmacy Department up to the maximum of \$1500.

Travel expenses to the Society of Critical Care Medicine including registration, airfare, hotel room, and meals for the conference will be reimbursed by the Pharmacy Department up to the maximum of \$1500.

Travel expenses to the Society of Infectious Diseases Pharmacists (SIDP) Annual Meeting / IDWeek or the Making A Difference in Infectious Diseases (MAD-ID) Annual Meeting including registration, airfare, hotel room, and meals for the conference will be reimbursed by the Pharmacy Department up to the maximum of \$1500.

If a pharmacy resident wishes to attend an additional professional conference, additional funding may be provided in accordance with the Trinity Health Travel and Other Business Expenses Finance Procedure, Trinity Health policy, Loyola Medicine policy, or departmental policy or procedure but is not guaranteed.



# **Appendix 1: PGY1 Pharmacy Residency Program Overview**

#### **Program Description:**

Loyola University Medical Center (LUMC) offers a one-year pharmacy residency beginning in the third week of June. The LUMC PGY1 pharmacy residency program prepares its graduates to assume positions in clinical and operations specialties employed by an institution or as a clinical faculty member employed by college of pharmacy. Graduates will be prepared to sit for the Board Certification exam in pharmacotherapy specialty. LUMC is a university teaching hospital providing the unique capability to engage each of our residents in direct patient care activities, research, administration and project management, and teaching skills.

PGY1 residents will gain the skills to function as the primary clinical pharmacist during their required core rotations, with the expectation that the resident will handle all aspects of the medication process from ordering to administration. Primary responsibilities include rounding with the multidisciplinary team(s), designing, recommending, monitoring, and evaluating patient-specific therapeutic regimens that incorporate the principles of evidence-based medicine, addressing all pharmacokinetic-monitored medications, being an active member of the Code Blue and Code Stroke teams, validating pharmacy orders for patients, and overseeing and directing pharmacy student activities as assigned. This integration of staffing and clinical services prepares residents for any type of practice environment they may encounter in their future jobs by emphasizing the development of essential skills required for an advanced pharmacy practitioner: independent practice skills, multi-tasking and prioritization.

Teaching activities include regular didactic presentations and preceptorship of pharmacy students. The ability to work independently and to supervise pharmacy students will be emphasized. The resident will also be involved in a research project. Scientific writing is strongly emphasized, and the preparation and submission of a manuscript suitable for publication will be expected.

#### PGY1 Competency Areas, Goals and Objectives (2024 Standard):

- I. Educational Outcome: broad categories of the residency graduates' capabilities.
  - a. Competency Area R1: Patient Care
  - b. Competency R2: Practice Advancement
  - c. Competency R3: Leadership
  - d. Competency R4: Teaching and Education
- II. Educational Goals: Goals listed under each outcome are broad sweeping statements of abilities.
- III. Educational Objectives: Resident achievement of educational goals is determined by assessment of the resident's ability to perform the associated educational objective below each educational goal.
- IV. The resident is encouraged to read detailed information about each goal at the ASHP website
  - a. https://www.ashp.org/-/media/assets/professional-development/residencies/docs/0825-COC-Decision-Updates/PGY1-Harmonized-CAGO-COC-BOD-Approved-2025-0918.pdf

#### Obligations of the Pharmacy Residency Program to the PGY1 Pharmacy Resident

- I. This program is a twelve-month, full-time position
- II. The PGY1 RPD will ensure that neither the educational outcomes of the program nor the welfare of the resident or the welfare of patients are compromised by excessive reliance on residents to fulfill service obligations.
- III. This program will comply with the current duty hour standards of the Pharmacy Specific Duty Hours Requirements for the ASHP Accreditation Standard for Pharmacy Residencies
- IV. This residency program will participate in and adhere to the rules of the RMP
- V. The RPD will provide PGY1 residents who are accepted into the program with a letter outlining their acceptance to the program.
  - a. Letter will contain terms and conditions of the appointment consistent with that provided to pharmacists within the organization conducting the residency
  - b. Will be signed and documented prior to the beginning of the residency
- VI. Loyola will provide a sufficient complement of professional and technical pharmacy staff to ensure appropriate supervision and preceptor guidance to all residents.
- VII. PGY1 residents will have a desk and computer where they can work, access to extramural educational opportunities (e.g., Midyear Clinical Meeting), and sufficient financial support to fulfill the responsibilities of the program.



- VIII. The RPD will award a certificate of residency to PGY1 residents who successfully complete the program
  - a. Will contain ASHP accreditation status
  - b. Will be signed by the RPD and the President
- IX. The RPD will ensure compliance with the provisions of the current version of the ASHP Regulations on Accreditation of Pharmacy Residencies



<u>Important Dates</u> <u>Deliverable</u>

July 1 NAPLEX and MPJE exams must be scheduled and taken

prior to July 1.

August 1 Mentor selection due

Committee Preferences ranking due Research Project and MUE topics due

Formal Journal Club topic due

August 15 CE Seminar topic due

September 1 IRB deadline, research project

October 1 ASHP Midyear Residency poster submission deadline

October 29 120 days after start date: Licensure deadline November 25 ASHP Midyear Poster due to printer (PGY1)

December 7-11, 2025 ASHP Midyear Clinical Meeting

December TLC portfolio complete

February 1 Case Presentation topic due Pharmacy Residency

Research Conference abstracts due

April 10 Pharmacy Residency Research Conference presentation

due

April/May Pharmacy Residency Research Conference
June 1 First draft Research Project Manuscript due

Third Monday in June Research Project Manuscript due (or prior to graduation

ceremony, whichever is earlier)



# Required Rotations

- Orientation
- Pharmacy Administration
- General Medicine
- Critical Care (Medical Intensive Care Unit, Surgical-Trauma Intensive Care Unit, Cardiovascular Intensive Care Unit, Neurosciences Intensive Care Unit, or Burn Intensive Care Unit)
- Acute/Critical Care Specialty (Cardiology, Hepatology, Hematology/Oncology, 2nd ICU, or Emergency Medicine)
- Infectious Diseases or Transplant Infectious Diseases
- Pediatrics (General Pediatrics/Pediatric Intensive Care Unit or Neonatal Intensive Care Unit)
- Transplant (Abdominal Transplant, Heart Transplant/Advanced Heart Failure, Lung Transplant, or Bone Marrow Transplant)
- Research (December)
- Pharmacy Operations (longitudinal)

# Elective Rotations

- Advanced General Medicine
- Outpatient heart transplant/advanced heart failure
- Pharmacy informatics
- Medication Safety
- Poison Center/Toxicology (offsite if available)
- MacNeal Hospital Emergency Medicine (offsite if available)
- MacNeal Hospital Intensive Care Unit (offsite if available)
- Any rotation listed under Required Rotations not previously taken
- LVAD longitudinal clinic (6 months, 1 day every other week see description below)

<sup>\*</sup>No travel funding provided for offsite rotations



#### Appendix 2: PGY2 Critical Care Pharmacy Residency Program Overview

#### **Program Description:**

Loyola University Medical Center (LUMC) offers a one-year specialty residency in critical care pharmacy practice beginning July 1st (start date may be adjusted on a case-by-case basis). The LUMC PGY2 critical care pharmacy residency program prepares its graduates to assume positions in critical care areas as a clinical specialist employed by an institution or as a clinical faculty member employed by college of pharmacy. Graduates will be prepared to sit for the Board Certification exam in critical care. LUMC is a university teaching hospital providing the unique capability to engage each of our residents in direct patient care activities, research, administration and project management, and teaching skills.

PGY2 residents will gain the skills to function as the primary ICU pharmacist during their required core ICU rotations, with the expectation that the resident will handle all aspects of the medication process from ordering to administration. Primary responsibilities include rounding with the ICU team(s), designing, recommending, monitoring, and evaluating patient-specific therapeutic regimens that incorporate the principles of evidence-based medicine, addressing all pharmacokinetic-monitored medications, being an active member of the code response team, validating pharmacy orders for ICU patients, and aiding preceptor in managing PGY1 resident and pharmacy student activities. This integration of staffing and clinical services prepares residents for any type of practice environment they may encounter in their future jobs by emphasizing the development of essential skills required for an advanced pharmacy practitioner: independent practice skills, multitasking and prioritization.

Teaching activities include regular didactic presentations, preceptorship of PGY1 pharmacy practice residents and fourth-year pharmacy students. The resident will also be involved in a research project and medication use evaluation. Scientific writing is strongly emphasized and the preparation and submission of a manuscript suitable for publication will be expected.

#### PGY2 Critical Care Competency Areas, Goals and Objectives (2016 Standard):

- I. Educational Outcome: broad categories of the residency graduates' capabilities.
  - a. Outcome R1: Patient Care
  - b. Outcome R2: Advancing Practice and Improving Patient Care
  - c. Outcome R3: Leadership and Management
  - d. Outcome R4: Teaching, Education, and Dissemination of Knowledge
- II. Educational Goals: Goals listed under each outcome are broad sweeping statements of abilities.
- III. Educational Objectives: Resident achievement of educational goals is determined by assessment of the resident's ability to perform the associated educational objective below each educational goal.
- IV. The resident is encouraged to read detailed information about each goal at the ASHP website (click on Critical Care Pharmacy [PGY2], 2016) https://www.ashp.org/professional-development/residency-information/residency-program-resources/residency-accreditation/pgy2-competency-areas

#### Obligations of the Pharmacy Residency Program to the PGY2 Critical Care Pharmacy Resident

- This program is a twelve-month, full-time position
- The PGY2 Critical Care RPD will ensure that neither the educational outcomes of the program nor the welfare of the resident or the welfare of patients are compromised by excessive reliance on residents to fulfill service obligations.
- This program will comply with the current duty hour standards of the Pharmacy Specific Duty Hours Requirements for the ASHP Accreditation Standard for Pharmacy Residencies
- This residency program will participate in and adhere to the rules of the RMP
- The RPD will provide PGY2 critical care residents who are accepted into the program with a letter outlining their acceptance to the program.
  - Letter will contain terms and conditions of the appointment consistent with that provided to pharmacists within the organization conducting the residency
  - Will be signed and documented prior to the beginning of the residency
- Loyola will provide a sufficient complement of professional and technical pharmacy staff to ensure appropriate supervision and preceptor guidance to all residents.
- PGY2 critical care residents will have a desk and computer where they can work, access to extramural
  educational opportunities (e.g., Midyear Clinical Meeting, the Society of Critical Care Medicine Congress), and
  sufficient financial support to fulfill the responsibilities of the program.



- The RPD will award a certificate of residency to PGY2 critical care residents who successfully complete the program (see PGY2 Critical Care Pharmacy Residency Graduation Checklist)
  - o Will contain ASHP accreditation status
  - Will be signed by the RPD and the Loyola president
- The RPD will ensure compliance with the provisions of the current version of the ASHP Regulations on Accreditation of Pharmacy Residencies

# **Critical Care Conference (CCC):**

- Required experience evaluated under Critical Care Conference (Longitudinal) LED
- Purpose: Provide a centralized discussion with a variety of preceptors for core topics as defined in the Critical Care topic appendix.
- The PGY2 resident will be expected to present 1-2 times per month on either a topic, journal club, or patient case.
- The PGY2 resident may also be expected to precept PGY1 presentations at CCC.



# **Loyola University Medical Center**

# PGY2 Critical Care Pharmacy Residency Program Graduation Checklist

Resident Name:

Category	Task/Deliverable	Objective	Date Completed	Preceptor Initials
	Receipt of checklist			·
	Receipt of manual/policies			
	Residency manual overview			
	Signed offer letter			
Orientation	Complete initial development plan within			
	PharmAcademic			
	Copy of PGY1 certificate within 30 days (upload to			
	PharmAcademic)			
	Illinois Pharmacist licensure (7/1)			
	Project defense presentation	2.2.1		
	IRB protocol	2.2.2		
Research Project	Abstract (Residency Conference)	2.2.6		
nescarell Project	Platform procentation (Pooldanes Conference)	2.2.3; 2.2.4; 2.2.5; 2.2.6; 4.1.3;		
	Platform presentation (Residency Conference)	4.1.4	<u> </u>	
	Publishable manuscript	3.2.2; 4.1.3		
	IRB protocol	2.1.2; 2.2.1; 2.2.2; 2.2.3		
MUE Project	Abstract (Midyear +/- Vizient)	2.1.2; 2.2.6		
MUE Project	Poster presentation (Midyear +/- Vizient)	2.1.2; 2.1.4; 2.2.4; 2.2.5; 2.2.6		
	P&T presentation	2.1.2; 2.1.4; 2.2.5		
	Continuing Education seminar	4.1.2; 4.1.3; 4.1.4; 4.2.1		
	Formal case presentation (2)			
Major Presentations	[average 70% SP of ACH on both]	4.1.1; 4.1.2; 4.1.3; 4.2.1		
Major Presentations	Formal journal clubs (2)			
	[average 70% SP of ACH on both]	4.1.1; 4.1.2; 4.1.3; 4.2.1		
	Critical Care Conference Topics	4.1.1; 4.1.2		
	Committee selection	1.3.2; 1.3.3; 2.1.1; 2.1.4		
Pharmacy Improvement	Ol project OR writing project	2.1.1; 2.2.1; 2.2.4; 2.2.5; 2.2.6;		
	QI project -OR- writing project	3.2.1		
	Inservice presentation (2)	4.1.1; 4.1.2; 4.1.3; 4.1.4		
	PharmAcademics submitted on time	3.1.2		
	Incident Reporting (2)	2.1.3; 2.1.4		
	Teaching and learning certificate awarded			
Clinical experiences	(PGY1 or at Loyola)			
	Teaching and Learning certificate lecture			
	(if completed as PGY1)	4.2.1		
	SCCM Abstract submission (optional)			
	Appendix topic list complete and turned in to RPD			
<u> </u>	>75% of objectives ACHR and at least SP on all			l
	objectives not ACHR			
Close-Out				
	ID badge, keys, etc. returned to RPD (as applicable)			
	Updated CV			

Signature upon receipt:	Signature upon completion:	
Resident (date):	Resident (date):	
RPD (date):	RPD (date):	



#### **Checklist for LUMC Critical Care PGY2 Pharmacy Resident**

The resident will demonstrate an understanding of the mechanism of action, pharmacokinetics, pharmacodynamics, pharmacogenomics, pharmacoeconomics, usual regimen (dose, schedule, form, route, and method of administration), indications, contraindications, interactions, adverse reactions, and therapeutics of medications and non-traditional therapies, where relevant, that are applicable to the diseases and conditions and have the ability to design appropriate treatment regimens and treat and assess outcomes. For some diseases and conditions, direct patient care is required. For other diseases and conditions, a case-based, didactic approach may be substituted. In these cases, the resident will demonstrate understanding of the diseases and condition via didactic instruction, case-based application, simulation, or other appropriate approach. For these diseases and conditions, the resident will demonstrate an understanding of signs and symptoms, epidemiology, risk factors and etiology, pathogenesis, pathophysiology, clinical course, and a comprehensive pharmacotherapy treatment plan. In the list, an asterisk (\*) indicates that direct patient care is required. The other items are required but may be covered in the case-based, didactic approach described above.

	Date/Learning experience completed	Format Completed	Initials of preceptor
Pulmonary			
*Acute respiratory distress syndrome			
*Severe asthma exacerbation			
3. *Acute COPD exacerbation			
4. *Acute pulmonary embolism			
5. *Acute pulmonary hypertension			
6. *Drug-induced pulmonary disease			
7. *Mechanical ventilation			
8. Chronic severe pulmonary hypertension			
9. Pneumothorax and hemothorax			
10. Chest tubes			
11. Cystic fibrosis			
12. Inhaled medication administration			
Cardiovascular			
*Advanced cardiac life support			
2. *Arrhythmias (atrial and ventricular)			
3. *Acute decompensated heart failure			
4. *Acute coronary syndromes			
5. *Hypertensive emergencies and urgencies			
6. *Shock syndromes			
7. Acute aortic dissection			
8. Pericardial tamponade			
9. Mechanical devices (e.g., intra-arterial balloon pumps, ECLS, ECMO)			
10. Invasive and non-invasive hemodynamic monitoring			
11. PALS			
Renal			
*Acute kidney injury		-	
2. *Acid-base imbalance			
3. *Fluid and electrolyte disorders			
4. *Contrast-induced nephropathy			
5. *Drug-induced nephropathy			



6.	Rhabdomyolysis		
7.	Syndrome of inappropriate antidiuretic hormone		
8.	Continuous renal replacement therapies/hemodialysis		
Ne	urology		
1.	*Status epilepticus		
2.	*Ischemic stroke		
3.	*Subarachnoid hemorrhage		
4.	*Intracerebral hemorrhage		
5.	*Critical illness polyneuropathy		
6.	Intracranial pressure management		
7.	Traumatic brain injury		
8.	Spinal cord injury		
9.	Central diabetes insipidus		
10.	Cerebral salt wasting		
11.	Encephalopathy in coma		
12.	EEG or bispectral monitoring for level of sedation		
13.	Ventriculostomies		
14.	Targeted temperature management/induced		
Ga	hypothermia strointestinal		
1.	*Acute upper and lower GI bleeding		
2.	*Acute pancreatitis		
3.	Fistulas		
4.	lleus		
5.	Abdominal compartment syndrome		
	patic		
1.	*Acute liver failure		
2.	*Complications of cirrhosis		
3.	*Drug-induced liver toxicity		
Dei	matology		
1.	Burns		
2.	Stevens-Johnson Syndrome		
3.	Toxic epidermal necrolysis		
4.	Erythema multiforme		
5.	Drug Reaction (or Rash) with Eosinophilia and		
1	Systematic Symptoms (DRESS)		
	nunology		
1.	Acute transplant rejection		
2.	Graft-versus-host disease		
3.	Management of the immunocompromised patient		
4.	Acute management of a solid organ or bone marrow transplant patient		
5.	Medication allergies/desensitization		
End	docrine	 	
1.	*Relative adrenal insufficiency		



2.	*Hyperglycemic crisis		
3.	*Glycemic control		
4.	Thyroid storm/ICU hypothyroid states		
Her	matology		
1.	*Acute venothromboembolism		
2.	*Coagulopathies		
3.	*Drug-induced thrombocytopenia		
4.	*Blood loss and blood component replacement		
5.	Anemia of critical illness		
6.	Drug-induced hematologic disorders		
7.	Sickle cell crisis		
8.	Methemoglobinemia		
Tox	ricology		
1.	*Toxidromes		
2.	*Withdrawal syndromes		
3.	Drug overdose		
4.	Antidotes/decontamination strategies		
Infe	ectious Diseases		
1.	*CNS infections		
2.	*Complicated intra-abdominal infections		
3.	*Pneumonia		
4.	*Endocarditis		
5.	*Sepsis		
6.	*Fever		
7.	*Antimicrobial stewardship		
8.	*Clostridium difficile associated diarrhea		
9.	Skin and soft-tissue infection		
	Urinary tract infections		
	Wound infections		
12.	Catheter-related infections		
	Infections in the immunocompromised host		
	Pandemic diseases		
	Febrile neutropenia		
	Acute osteomyelitis		
Sup	oportive Care		
1.	*Pharmacokinetic and pharmacodynamic alterations in critically ill		
2.	*Nutrition (enteral, parenteral nutrition, considerations in special populations)		
3.	*Analgesia		
4.	*Sedation		
5.	*Delirium		
6.	*Sleep disturbances		
7.	*Rapid sequence intubations		
8.	*Venous thromboembolism prophylaxis	 	



9. *Stress ulcer prophylaxis		
10. Pharmacogenomic implications		
11. Oncologic emergencies		
12. Other devices		
Intravascular devices		
Peripheral nerve stimulators		
IV pumps related topics		
The resident will be able to describe key landmark events in	the evolution of critical care pharmacy a	s a specialty and

Program Director Signature			<u>-</u>
Resident Signature		 Date	<u> </u>
The resident will be able to describe key landmark summarize the findings from key studies document health care outcomes.			
	L		l
<ol><li>IV pumps related topics</li></ol>			
Z. 1 cripricial fierve stillidiators			



# Appendix 3: PGY2 Solid Organ Transplant Pharmacy Residency Program Overview

Loyola University Medical Center (LUMC) offers a one-year specialty residency in solid organ transplant pharmacy practice beginning July 1st (start date may be adjusted on a case-by-case basis)

#### **Program Description:**

The LUMC PGY2 Solid Organ Transplant pharmacy residency program prepares its graduates to assume positions in solid organ transplant areas as a clinical specialist employed by an institution or as a clinical faculty member employed by college of pharmacy. LUMC is a university teaching hospital providing the unique capability to engage each of our residents in direct patient care activities, research, administration and project management, and teaching skills.

PGY2 residents will gain the skills to function as the primary transplant pharmacist during their required core rotations, with the expectation that the resident will handle all aspects of the medication process from ordering to administration. Primary responsibilities include rounding with the transplant team(s), designing, recommending, monitoring, and evaluating patient-specific therapeutic regimens that incorporate the principles of evidence-based medicine, addressing all pharmacokinetic-monitored medications, being an active member of the Multidisciplinary Review Boards (MRBs) and Quality Assessment/Process Improvement (QAPI) meetings, validating pharmacy orders for transplant patients, and aiding preceptor with managing PGY1 resident and pharmacy student activities. This integration of staffing and clinical services prepares residents for any type of practice environment they may encounter in their future jobs by emphasizing the development of essential skills required for an advanced pharmacy practitioner: independent practice skills, multitasking and prioritization.

Teaching activities include regular didactic presentations, preceptorship of PGY1 pharmacy practice resident and fourth year pharmacy students, and hepatology/nephrology/infectious disease fellows conference presentations. The resident will also be involved in a research project, a medication use evaluation and a writing project. Scientific writing is strongly emphasized and the preparation and submission of a manuscript suitable for publication will be expected.

#### PGY2 Solid Organ Transplant Competency Areas, Goals and Objectives (2018 Standard):

- Educational Outcome: broad categories of the residency graduates' capabilities.
  - o Outcome R1: Patient Care
  - o Outcome R2: Advancing Practice and Improving Patient Care
  - Outcome R3: Leadership and Management
  - Outcome R4: Teaching, Education, and Dissemination of Knowledge
- Educational Goals: Goals listed under each outcome are broad sweeping statements of abilities.
- Educational Objectives: Resident achievement of educational goals is determined by assessment of the resident's ability to perform the associated educational objective below each educational goal.
- The resident is encouraged to read detailed information about each goal at the ASHP website (click on Solid Organ Transplant Pharmacy [PGY2], 2018)
  - https://www.ashp.org/Professional-Development/Residency-Information/Residency-Program-Directors/Residency-Accreditation/PGY2-Competency-Areas

#### Obligations of the Pharmacy Residency Program to the PGY2 Solid Organ Transplant Pharmacy Resident

- > This program is a twelve-month, full time position
- > The PGY2 Solid Organ Transplant RPD will ensure that neither the educational outcomes of the program nor the welfare of the resident or the welfare of patients are compromised by excessive reliance on residents to fulfill service obligations.
- > This program will comply with the current duty hour standards of the Pharmacy Specific Duty Hours Requirements for the ASHP Accreditation Standard for Pharmacy Residencies.
- > This residency program will participate in and adhere to the rules of the RMP.
- The RPD will provide PGY2 solid organ transplant residents who are accepted into the program with a letter outlining their acceptance to the program.
  - Letter will contain terms and conditions of the appointment consistent with that provided to pharmacists within the organization conducting the residency.



- Letter will be signed and documented prior to the beginning of the residency.
- Loyola will provide a sufficient complement of professional and technical pharmacy staff to ensure appropriate supervision and preceptor guidance to all residents.
- ➤ PGY2 solid organ transplant residents will have a desk and computer where they can work, access to extramural educational opportunities (e.g., Transplant Fellows Symposium, Midyear Clinical Meeting, the American Transplant Congress), and sufficient financial support to fulfill the responsibilities of the program.
- The RPD will award a certificate of residency to PGY2 solid organ transplant residents who successfully complete the program ((see PGY2 Solid Organ Transplant Pharmacy Residency Graduation Checklist)
  - The residency certificate will be signed by the RPD and the Loyola President.
- The RPD will ensure compliance with the provisions of the current version of the ASHP Regulations on Accreditation of Pharmacy Residencies

#### Solid Organ Transplant Conference

The PGY2 transplant pharmacy resident will participate in a weekly resident-driven meeting for the resident to provide a centralized discussion with a variety of preceptors for core topics as defined in the Solid Organ Transplant topic appendix. This is a required experience evaluated under Solid Organ Transplant (SOT) Conference (Longitudinal). The meeting may be in the format of a topic discussion, journal club, or case review. A tentative calendar will be provided; however, the resident will have input based on their perceived educational needs.

# **Program Structure**

- Required Rotations (4-5 weeks unless otherwise specified)
  - Abdominal Transplant
  - Abdominal Transplant Outpatient
  - Heart Transplant/Advanced Heart Failure
  - o Lung transplant
  - Hepatology
  - Orientation
  - o Transplant Infectious Diseases
  - Must select at least one advanced inpatient organ rotation per resident preference
    - Advanced Abdominal Transplant Inpatient
    - Advanced Lung Transplant
    - Heart Transplant/Advanced Heart Failure II
- Remainder of rotation schedule comprised of other solid organ transplant electives or other clinical areas as specified in the Clinical and Administration Rotations Table
- Required Longitudinal Experiences
  - Continue Education Seminar (Longitudinal)
  - Pharmacy Clinical Staffing (Longitudinal)
  - o Practice Management/Pharmacy Improvement (Longitudinal)
  - Research Project (Longitudinal)
  - o Solid Organ Transplant (SOT) Conference (Longitudinal)
  - Teaching and Learning Certificate (if not completed as PGY1)
- Required project deliverables outlined below in the graduation checklist



# PGY-2 Solid Organ Transplant Residency Requirements Checklist (Evaluated quarterly)

(Evaluated quarterly)

<u>ASHP Requirements</u>

#### **Resident Name:**

Resident Name:			
Task	Objective	Date Completed	Preceptor Initial
Orientation	•		1
Sign this checklist to confirm receipt			
Signed offer/acceptance letter			
Curriculum vitae (day 1)			
Entering Objective-Based Self-Evaluation (PharmAcademic)			
ASHP Entering Interests Form (PharmAcademic)			
Copy provided of PGY1 certificate within 30 days (upload to			
PharmAcademic)			
Pharmacist Licensure within 120 days after start date			
Pharmacy Improvement		1	
Order set, guideline, protocol, or other initiative implemented	R2.1.1, R3.2.1		
Writing Project	R2.1.1, R4.1.3, R		
	4.1.1		
MUE Project	R1.3.2, R2.1.1,		
	R2.1.3, R4.1.1, R4.1.2, R4.1.3,		
	R4.1.4		
Research Project	•	•	1
Research Defense Presentation	R2.2.1, R2.2.2		
IRB protocol	R2.2.1, R2.2.2		
ATC Abstract submission	R 2.2.1, R2.2.2,		
7 TO 7 IDST dot Submission	R2.2.3, R2.2.6		
Research Poster Presentation	R 2.2.1, R2.2.2,		
	R2.2.3, R2.2.4, R2.2.5, R2.2.6		
Research Manuscript (appropriate for submission to journal)	R2.2.5, R2.2.6		
Other presentations			
Continuing education seminar	R4.1.1, R4.1.2,	1	
	R4.1.3, R4.1.4		
SOT Conference Topics	R4.1.1, R4.1.2,		
Olivita at Farmanian and	R4.1.3, R4.2.1		
Clinical Experiences	D444 D442	-	
Teaching and Learning Certificate (if not completed during	R4.1.1, R4.1.2, R4.1.3, R4.1.4,		
PGY1)	R4.2.1		
Teaching and Learning Certificate lecture (if completed as PGY1	)R4.2.1		
Complete all assigned PharmAcademic evaluations and	R3.1.2		
customized plan updates			
Complete Solid Organ Transplant Appendix. Signed by			
preceptors and submitted to RPD			
Close Out			
Updated curriculum vitae			
ID Badge, Pager, Keys, etc Returned to RPD			
≥ 75% of objectives achieved for residency and receipt of a	1		
minimum of "satisfactory progress" on all objective not marked a	s		
"achieved for residency"			
Final program summative evaluation completed based			
on previous summative evaluations (quarterly evaluations,			
rotation summative evaluations, etc.) by the RPD			
Satisfactory completion of all rotations as determined by the		1	
primary preceptor for each rotation			
F F. Sooktor for each formuch	L	I .	1

Signature Upon Receipt:

Signature Upon Completion:



Resident:	Resident:
RPD:	RPD:



# **Checklist for LUMC PGY2 Solid Organ Transplant Pharmacy Resident**

The resident will demonstrate an understanding of the mechanism of action, pharmacokinetics, pharmacodynamics, pharmacogenomics, pharmacoeconomics, usual regimen (dose, schedule, form, route, and method of administration), indications, contraindications, interactions, adverse reactions, and therapeutics of medications and non-traditional therapies, where relevant, that are applicable to the diseases and conditions and have the ability to design appropriate treatment regimens and treat and assess outcomes. For some diseases and conditions, direct patient care is required. For other diseases and conditions, a case-based, didactic approach may be substituted. In these cases, the resident will demonstrate understanding of the diseases and condition via didactic instruction, case-based application, simulation, or other appropriate approach. For these diseases and conditions, the resident will demonstrate an understanding of signs and symptoms, epidemiology, risk factors and etiology, pathogenesis, pathophysiology, clinical course, and a comprehensive pharmacotherapy treatment plan. In the list, an asterisk (\*) indicates that direct patient care is required. The other items are required but may be covered in the case-based, didactic approach described above.

		Date/Learning experience completed	Format Completed	Initials of preceptor
	insplant Overview		_	
1.	History of solid organ transplant and associated			
	outcomes			
	Basics of transplant immunology			
	eases or conditions that are an indication for transplanta	tion		
1.	*Kidney transplantation			
2.	*Pancreas and/or islet cell transplantation			
3.	*Liver transplantation			
4.	Intestinal transplantation			
5.	*Heart transplantation			
6.	*Lung transplantation			
	e-transplant phase			
1.	*Pre-transplant evaluation review (in person or chart			
	review)			
2.	Contraindications to transplant (relative and absolute)			
3.	Sensitizing factors			
4.	Considerations for induction and maintenance			
_	immunosuppression			
5.	Immunizations			
6.	Care of patients with end-stage organ disease (e.g.			
	cystic fibrosis, complications of cirrhosis, mechanical			
De	circulatory devices)			
	ri-operative phase			
	Basics of transplant surgical procedure			
2.	Organ procurement			
3.	Preservation process	otiono		
	e- and intra-operative transplant pharmacologic consider	alions		
1. 2.	*Induction considerations			
	Desensitization strategies			
3.	ABO-incompatible transplant strategies			
4.	<ul><li>Induction types:</li><li>Lymphocyte depleting</li></ul>			
Da	Non-lymphocyte depleting st-transplant pharmacologic considerations			
1.	*Maintenance			
1.	immunosuppression/immunomodulation			
	considerations			
2	Maintenance immunosuppression strategies			
۷.	Antimetabolites			
<u></u>	Calcineurin inhibitors and minimization			



	Corticosteroids and			
	avoidance/withdrawal/minimization			
	Costimulation inhibitors			
	mTOR inhibitors			
Re	jection and treatment strategies			
1.	*Acute cellular rejection			
2.	*Acute antibody mediated rejection			
3.	Chronic rejection			
Infe	ection considerations	1	!	
1.	*Infection prophylaxis, monitoring and treatment			
	strategies			
2.	*Surgical infectious prophylaxis			
3.	Adenovirus			
4.	BK polyomavirus nephropathy and screening and			
	treatment			
5.	Central venous catheter infections and treatment			
	options			
6.	CMV and EBV			
7.	Fungus (e.g Candida sp., Aspergillus sp., Endemic			
	fungi)			
8.	Hepatitis B virus prophylaxis and treatment			
9.				
10.	Herpes simplex and zoster			
	Human immunodeficiency virus			
	Immunizations post-transplant			
	Infectious exposure management			
	Measles			
	Varicella			
14.	Mycobacteria			
	Nocardia			
16.	Parasites			
17.	Parvovirus B19			
	Pneumocystis pneumonia			
	Sepsis			
20.	Tuberculosis			
21.	Urinary tract infections/pyelonephritis			
	st-transplant malignancy considerations	1		
1.	Post-transplant lymphoproliferative disease (PTLD)			
2.	Risk of new malignancy or recurrent malignancy			
Oth	ner post-transplant medical considerations			
1.	Management of pregnancy in transplantation			
2.	Cardiovascular (e.g. cardiovascular risk			
	management, congestive heart failure (CHF),			
	coronary artery disease (CAD), hemodynamic			
	conditions, hyperlipidemia, hypertension)			
3.	Endocrine (e.g. Post-transplant diabetes mellitus			
	(PTDM), metabolic diseases (metabolic syndrome),			
	hyperparathyroidism, osteoporosis/bone disease,			
	gout, pancreatitis, pediatric growth impairment)			
4.	Gastrointestinal (e.g.			
	malnutrition/anorexia/nausea/vomiting/diarrhea,			
	eosinophilic esophagitis)			
5.	Hematologic (e.g. bone marrow suppression			
	(leukopenia, anemia, thrombocytopenia), post-			
	transplant erythrocytosis (PTE))			
6.	Hepatic (e.g. biliary complications and management,			
	hepatotoxicity)			



depression, headache, neurogenic bladder)  8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Strategies to improve nonadherence  • Strategies to improve nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs  Transplant regulations and quality  1. UNOS/Organ Procurement and Transplantation Network regulations  2. Centers for Medicare and Medicaid Services regulations  3. Risk Evaluation and Mitigation Strategies  4. Organ allocation  5. Medication distribution programs  the resident will be able to describe key landmark events in the evolution of solid or pecialty and summarize the findings from key studies documenting the association avorable health care outcomes.	<del></del>	
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs  Transplant regulations and quality  1. UNOS/Organ Procurement and Transplantation Network regulations  2. Centers for Medicare and Medicaid Services regulations  3. Risk Evaluation and Mitigation Strategies  4. Organ allocation  5. Medication distribution programs  the resident will be able to describe key landmark events in the evolution of solid or pecialty and summarize the findings from key studies documenting the association		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs  Transplant regulations and quality  1. UNOS/Organ Procurement and Transplantation Network regulations  2. Centers for Medicare and Medicaid Services regulations  3. Risk Evaluation and Mitigation Strategies  4. Organ allocation		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs  Transplant regulations and quality  1. UNOS/Organ Procurement and Transplantation Network regulations  2. Centers for Medicare and Medicaid Services regulations  3. Risk Evaluation and Mitigation Strategies  4. Organ allocation		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs  Transplant regulations and quality  1. UNOS/Organ Procurement and Transplantation Network regulations  2. Centers for Medicare and Medicaid Services regulations		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs  Transplant regulations and quality  1. UNOS/Organ Procurement and Transplantation Network regulations		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs  Transplant regulations and quality		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access  • Private vs. public  • Patient assistance programs		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care  3. Medication and medical access		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence  2. Pediatric to adult transition of care		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence  • Consequences of nonadherence  • Factors impacting nonadherence  • Strategies to improve nonadherence		
<ol> <li>Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)</li> <li>Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)</li> <li>Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)</li> <li>Psychosocial concerns</li> <li>Nonadherence         <ul> <li>Consequences of nonadherence</li> <li>Factors impacting nonadherence</li> </ul> </li> </ol>		$\dashv$
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns  1. Nonadherence		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)  Psychosocial concerns		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis and treatment)		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding, hydronephrosis, ischemia/reperfusion injury, lymphocele, obstruction/leak, pain, primary graft nonfunction, technical graft loss, thrombosis prophylaxis		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular acidosis)  10. Surgical/technical complications (e.g. bleeding,		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)  9. Renal (e.g. acute tubular necrosis (ATN), calcineurin inhibitor nephrotoxicity, dehydration, electrolyte imbalances, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, proteinuria, renal tubular		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing pneumonia (BOOP), interstitial pneumonitis, pulmonary edema)		
8. Pulmonary (e.g. Bronchiolitis obliterans organizing		
denression neadache neurodenic niadder)		
7. Neurological (e.g. Calcineurin inhibitor neurotoxicity,		
	ession, headache, neurogenic bladder) onary (e.g. Bronchiolitis obliterans organizing monia (BOOP), interstitial pneumonitis,	ession, headache, neurogenic bladder) onary (e.g. Bronchiolitis obliterans organizing monia (BOOP), interstitial pneumonitis,



# Appendix 4: PGY2 Infectious Diseases Pharmacy Residency Program Overview

#### **Program Description:**

Loyola University Medical Center (LUMC) offers a one-year specialty residency in infectious diseases pharmacy practice beginning July 1<sup>st</sup> (start date may be adjusted on a case-by-case basis). The LUMC PGY2 infectious diseases pharmacy residency program prepares its graduates to assume positions in infectious diseases and antimicrobial stewardship as a clinical specialist employed by an institution or as a clinical faculty member employed by a college of pharmacy. Graduates will be prepared to sit for the Board Certification exam in infectious diseases (BCIDP). LUMC is a university teaching hospital providing the unique capability to engage each of our residents in direct patient care activities, research, administration and project management, and teaching skills.

The PGY2 ID resident will gain the skills to function as an independent infectious diseases and antimicrobial stewardship pharmacist during their required core rotations. The resident will manage ID pharmacotherapy for a variety of medical and surgical inpatients, including critically ill and immunocompromised populations. Antimicrobial stewardship training will allow an opportunity for the resident to develop leadership skills and collaborate with multiple disciplines on quality improvement initiatives, guideline development, and education, while also promoting safe and effective use of antimicrobials. LUMC is designated as an Antimicrobial Stewardship Center of Excellence, which the PGY2 ID resident will make meaningful contributions towards the continued success of the program. As a member of the infectious diseases consult service, the resident will develop communication skills to effectively convey recommendations and facilitate the implementation of said recommendations in conjunction with bedside pharmacists throughout the hospital. Additional rotations will broaden the residents' perspective on clinically complex patients and provide foundational experiences in microbiology and infection control.

Teaching activities include didactic presentations for the infectious diseases medical fellows, preceptorship of PGY1 pharmacy residents and fourth year pharmacy students. The ability to work independently and to supervise pharmacy residents and students will be emphasized, particularly in the latter half of the residency year. The resident will also complete a research project and formal medication use evaluation. Scientific writing is strongly emphasized and the preparation and submission of a manuscript suitable for publication will be expected.

#### PGY2 Infectious Diseases Competency Areas, Goals, and Objectives (2017 standards)

- Educational Outcome: broad categories of the residency graduates' capabilities.
  - o Outcome R1: Patient Care
  - Outcome R2: Advancing Practice and Improving Patient Care
  - Outcome R3: Leadership and Management
  - o Outcome R4: Teaching, Education, and Dissemination of Knowledge
- Educational Goals: Goals listed under each outcome are broad sweeping statements of abilities.
- Educational Objectives: Resident achievement of educational goals is determined by assessment of the resident's ability to perform the associated educational objective below each educational goal.

# Obligations of the Pharmacy Residency Program to the PGY2 Infectious Diseases Pharmacy Resident

- I. The program is a twelve-month, full-time position
- II. The PGY2 Infectious Diseases RPD will ensure that neither the educational outcomes of the program nor the welfare of the resident or the welfare of patients are compromised by excessive reliance on residents to fulfill service obligations
- III. This program will comply with the current duty hour standards of the Pharmacy Specific Duty Hours Requirements for the ASHP Accreditation Standard for Pharmacy Residencies
- IV. This residency program will participate in and adhere to the rules of the RMP
- V. The RPD will provide PGY2 infectious diseases pharmacy residents who are accepted into the program with a letter outlining their acceptance to the program
  - a. Letter will contain terms and conditions of the appointment consistent with that provided to pharmacists within the organization conducting the residency
  - b. Will be signed and documented prior to the beginning of the residency
- VI. Loyola will provide a sufficient complement of professional and technical pharmacy staff to ensure appropriate supervision and preceptor guidance to all residents
- VII. PGY2 infectious diseases residents will have a desk and computer where they can work, access to extramural educational opportunities (e.g., Midyear Clinical Meeting, IDWeek / SIDP Annual Meeting or MAD-ID), and sufficient financial support to fulfill the responsibilities of the program



- VIII. The RPD will award a certificate of residency to PGY2 infectious diseases residents who successfully complete the program (see PGY2 Infectious Diseases Pharmacy Residency Certificate section)
  - a. Will contain ASHP accreditation status
  - b. Will be signed by the RPD and the Loyola President
- IX. The RPD will ensure compliance with the provisions of the current version of the ASHP Regulations on Accreditation of Pharmacy Residencies

#### **Program Structure**

- Required Rotations (4-5 weeks unless otherwise specified)
  - Antimicrobial Stewardship
  - Advanced Antimicrobial Stewardship
  - o General Infectious Diseases Consults
  - o Advanced General infectious Diseases Consults
  - Transplant Infectious Diseases
  - Microbiology (2 weeks)
  - At least one infectious diseases elective per resident preference
    - Pediatric Infectious Diseases
    - Community Hospital Infectious Diseases
    - Advanced Transplant Infectious Diseases
- Remainder of rotation schedule comprised of other infectious diseases electives or other clinical areas as specified in the <u>Clinical and Administration Rotations Table</u>
- Required Longitudinal Experiences
  - Outpatient Parenteral Antimicrobial Therapy (OPAT) (6 months)
  - Research Project (12 months)
  - Continuing Education Seminar (6 months)
  - Medication Use Evaluation (MUE) (12 months)
  - Writing Project (6 months)
  - Stewardship Administration (includes committee involvement) (12 months)
  - Teaching and Learning Certificate (if not completed as PGY1) (12 months)
  - Pharmacy Clinical Staffing (12 months)
  - o ID Conference (12 months)
- Required project deliverables outlined below in the graduation checklist



# Loyola University Medical Center

# PGY2 Infectious Diseases Pharmacy Residency Program Graduation Checklist

#### Resident Name:

Category	Task/Deliverable (with applicable deadlines)	Objective	Date Completed	Preceptor Initials
Onboarding	Signed offer letter			
	Take licensure exams (7/1)			
Orientation	Receipt of checklist			
	Receipt of manual / policies			
	Residency manual overview			
	Complete initial development plan within PharmAcademic			
	Copy of PGY1 certificate provided to RPD (no later than 30 days			
	after start date)			
	Illinois Pharmacist licensure (no later than 120 days after start			
	date)			
Research	Research project selection (8/1)	2.2.1		
Project	Project defense presentation	2.2.1		
	IRB protocol	2.2.2		
	Abstract (Residency Conference)	2.2.6		
	Platform presentation (Residency Conference)	2.2.3; 2.2.4; 2.2.5;		
		2.2.6; 4.1.3; 4.1.4		
	Abstract (SIDP / MADID or IDWeek) (optional)	2.2.6		
	Poster presentation (SIDP/MAD-ID or IDWeek) (optional)	2.2.3; 2.2.4; 2.2.5;		
		2.2.6; 4.1.3		
	Publishable manuscript	3.2.2; 4.1.3		
MUE Project	MUE project selection (8/1)	2.2.1		
	IRB protocol	2.2.1; 2.2.2; 2.2.3		
	Abstract (Midyear +/- Vizient)	2.2.6		
	Poster presentation (Midyear +/- Vizient)	2.1.3; 2.2.5; 2.2.6;		
		4.1.2		
	P&T presentation	2.1.1; 2.1.3; 2.2.5		
Major	Continuing Education seminar topic selection (8/15)			
Presentations	Continuing Education seminar presentation	4.1.1; 4.1.2; 4.1.3;		
		4.1.4; 4.2.1		
	Formal case presentation (2)	4.1.1; 4.1.2; 4.1.3		
	Formal journal clubs (2)	4.1.1; 4.1.2; 4.1.3		
	ID Conference topics	4.2.2		
Writing Project	Publishable manuscript	2.2.6; 4.1.3; 4.1.4		
Stewardship	Committee selection / involvement (local or regional ASP	1.3.1; 1.3.2; 1.3.3;		
Administration	Committee)	2.3.2; 3.3.1		
	QI Project (policy, guideline, or protocol development / update)	2.1.1; 2.1.3; 2.3.1; 3.3.1		
Other	Teaching and Learning Certificate awarded (PGY1 or at Loyola)			
Experiences	Teaching and Learning Certificate lecture (if completed as PGY1)	4.2.1		
	Incident reporting (VOICE) (2)	2.1.3		
Close-Out	PharmAcademics On Time Completion	3.2.2		
	Submit all final projects to PharmAcademic			
	Topic List and Experience List submitted to PharmAcademic			
	> 75% of objectives ACHR and at least SP on all objectives not	1	1	
	ACHR			
	ID badge, keys, etc. returned to RPD (as applicable)			1

Signature upon receipt	Signature upon completion
Resident (date):	Resident (date):
RPD (date):	RPD (date):



# Loyola University Medical Center

# PGY2 Infectious Diseases Pharmacy Residency Program Topic Discussion List

#### Resident Name:

Торіс	Date Completed	Preceptor Initial
Bone and joint infections*		
Cardiovascular infections / endocarditis*		
Central nervous system infections*		
Fever of unknown origin		
Fungal infections*		
Invasive candidiasis		
Dimorphic fungi		
Aspergillosis		
Mucormycosis		
Gastrointestinal infections, including C difficile infections*		
Hepatitis B		
Hepatitis C		
HIV infections and AIDS		
Intra-abdominal infections*		
Neutropenic fever*		
Ophthalmologic infections		
Opportunistic infections in immunocompromised hosts*		
Pneumocystis (PJP)		
Toxoplasmosis		
Nocardia		
Parasitic infections		
Reproductive organ infections		
Respiratory tract infections (upper and lower)*		
Rickettsial infections		
Sepsis*		
Sexually transmitted diseases		
Skin and soft tissue infections*		
Tuberculosis and other mycobacterial infections		
Travel medicine		
Urologic infections*		
Viral infections*		
HSV / VZV		
CMV		
Adenovirus		
EBV		
BK virus		
Parvovirus		
RSV		
*Pour les districts and a start and a star		

Signature upon completion
Resident (date):
RPD (date):

<sup>\*</sup>Requires direct patient care - resident will document estimated number of encounters in the Patient Care Experience tracker.



# **Appendix 5: Duty Hour Requirements**

#### **Definitions:**

**Duty Hours:** Duty hours are defined as all scheduled clinical and academic activities related to the pharmacy residency program. This includes inpatient and outpatient care; in-house call; administrative duties; and scheduled and assigned activities, such as conferences, committee meetings, and health fairs that are required to meet the goals and objectives of the residency program. Duty hours must be addressed by a well-documented, structured process. Duty hours do not include reading, studying, and academic preparation time for presentations and journal clubs; travel time to and from conferences; and hours that are not scheduled by the residency program director or a preceptor.

Please refer to the following website for ASHP's duty hour requirements: <u>ashp.org/-</u>/media/assets/professional-development/residencies/docs/duty-hour-requirements.ashx

**Scheduled duty periods:** Assigned duties, regardless of setting, that are required to meet the educational goals and objectives of the residency program. These duty periods are usually assigned by the residency program director or preceptor and may encompass hours which may be within the normal workday, beyond the normal workday, or a combination of both.

#### **Duty-Hour Requirements:**

Residents, program directors, and preceptors have the professional responsibility to ensure they are fit to provide services that promote patient safety. The residency program director (RPD) must ensure that there is not excessive reliance on residents to fulfill service obligations that do not contribute to the educational value of the residency program or that may compromise their fitness for duty and endanger patient safety. Providing residents with a sound training program must be planned, scheduled and balanced with concerns for patients' safety and residents' well-being. Therefore, programs must comply with the following duty-hour requirements:

- I. Personal and Professional Responsibility for Patient Safety
  - a. Residency program directors must educate residents and preceptors about their professional responsibilities to be appropriately rested and fit for duty to provide services required by patients.
  - b. Residency program directors must educate residents and preceptors to recognize signs of fatigue and sleep deprivation and adopt processes to manage negative effects of fatigue and sleep deprivation to ensure safe patient care and successful learning.
  - c. Residents and preceptors must accept personal and professional responsibility for patient care that supersedes self-interest. At times, it may be in the best interest of patients to transition care to another qualified, rested provider.
  - d. The residency program director must ensure that residents participate in structured handoff processes when they complete their duty hours to facilitate information exchange to maintain continuity-of-care and patient safety.
- II. Maximum Hours of Work per Week and Duty-Free Times
  - a. Duty hours must be limited to 80 hours per week, averaged over a four-week period, inclusive of all in-house call activities and all moonlighting.
  - b. Moonlighting is defined as voluntary, compensated, work performed outside the organization (external) or within the organization (internal) or at any of the residency's



related participating sites. These are compensated hours beyond the residents' salary and are not part of the scheduled duty periods of the residency program.

- i. Moonlighting must not interfere with the ability of the resident to achieve the educational goals and objectives of the residency program.
  - 1. All moonlighting hours must be counted towards the 80-hour maximum weekly hour limit.
  - 2. Programs that allow moonlighting must have a documented structured process to monitor moonlighting that includes at a minimum:
    - a. The type and number of moonlighting hours allowed by the program.
- ii. Pharmacy residents may be allowed to moonlight internally within LUMC by staffing shifts in the LUMC inpatient pharmacy or the outpatient pharmacy provided that this does not interfere with regularly scheduled residency activities including rotation commitments and project commitments. Any unscheduled staffing shifts (e.g. sick call coverage) will be considered moonlighting and will be compensated accordingly. Any internal moonlighting must be approved by the RPD. In addition, the resident must adhere to the following rules regarding "moonlighting":
  - 1. The resident must notify the RPD of any planned staffing shifts in writing for approval via email.
  - 2. Moonlighting may not exceed 8 hours in a given 7-day period.
  - 3. Moonlighting hours will be counted toward the 80 hour per week maximum
  - 4. Moonlighting must not interfere with resident job performance.
- iii. If a resident is suspected or found to be impaired due to moonlighting while on scheduled duty hours, the resident will be dismissed for the remainder of the workday and will be required to cease moonlighting activities.



# **Appendix 6: Additional Pharmacy Resident Benefits and Services**

#### Miscellaneous Benefits

Loyola provides several benefits to the pharmacy resident other than medical, dental, and vision insurance. Examples include long- and short-term disability, life insurance, retirement savings options, flexible spending accounts, and others. Detailed information on these benefits can be found on HR4U.

# Family Medical Leave Act

It is the policy of Loyola to grant pharmacy residents family leave in accordance with the Family and Medical Leave Act ("FMLA") of 1993. The intent is to provide pharmacy residents with up to twelve (12) weeks of job protected leave during any twelve (12) month period. To be eligible for leave, a pharmacy resident must have been employed by Loyola for at least twelve months and worked for at least 1250 hours in the twelve months preceding the leave. A pharmacy resident may request FMLA leave to care for an immediate family member (spouse, child, or parent) who has a serious health condition; the birth, adoption, or foster care placement of a child; for his/her own serious health condition; to care for a spouse, child or next of kin with illness or injury incurred in the line of duty while in the Armed Forces, National Guard or Reserves; or due to any qualifying exigency arising out of the fact that a spouse, child or parent is on active duty or has been notified of an impending call or order to active duty in the Armed Forces in support of a contingency operation. Eligibility for and execution of leaves of absence as requested by the resident under FMLA will be as outlined in Trinity Health Human Resources Ministry-Wide Policy No. 1024: Family Medical Leave Act (FMLA) for Non-Military Leave, Policy No. 1027 Elective and Other Leaves of Absence, or Policy No. 1025 FMLA Military Leave, FMLA is unpaid leave, and the resident's standard salary / stipend will be paused while on leave. However, the resident will be required to use available paid time off as outlined in policy while on leave. Salary / stipend will resume upon return to work and will then continue until completion of the program, including any extension needed to fulfill the requirements for graduation from the program.

Pharmacy residents must submit requests for FMLA leave in writing as soon as possible prior to the beginning of leave. The pharmacy resident shall provide the RPD with a copy of the request and contact the FMLA administrator as outlined in policy. Additional information on the FMLA process can be found on the HR4U website. Where applicable, the pharmacy resident must also complete appropriate forms with the Department of Human Resources to continue medical, dental, life insurance and long-term disability coverage during the FMLA leave. If any portion of the resident's leave is unpaid or salary is insufficient to cover the cost of continued benefits, the cost will be collected in arrears upon return to work in accordance with payroll standard procedures. If the FMLA leave exceeds the allowable absence by specific board requirements or causes the resident to miss a key rotation, the pharmacy resident must extend his/her training to complete the requirements and/or rotation.



# **Maternity/Paternity Leave of Absence**

It is the policy of Loyola to grant pharmacy residents maternity/paternity leave for the birth, adoption, or foster care placement of a child. In granting maternity/paternity leaves, Loyola will follow the requirements of the Family Medical Leave Act of 1993, as outlined above.

#### **Personal Leave of Absence**

A pharmacy resident may request a personal leave of absence from the RPD. Requests for leave of absence in the first twelve (12) months of training are limited to situations that would not otherwise be covered by the Family Medical Leave Act (FMLA). Leave of absences for reasons other than this during the first twelve months of training are not allowed. Eligibility for and execution of personal leaves of absence will be as outlined in Trinity Health Human Resources Ministry-Wide Policy No. 1027: Elective and Other Leaves of Absence (Non-FMLA and Non-Military).

To begin the process, the pharmacy resident must submit a written request to the program director at least 30 days prior to the beginning of the leave (except in case of emergency) that contains the reason(s) for the leave and anticipated beginning and return dates. Confidentiality as to the reason for the leave shall be respected when requested and as outlined in policy. The resident shall then contact the FMLA leave administrator and complete any required steps as outlined in policy and by the administrator.

A leave of absence should not exceed eight weeks. Benefits coverage is continued during leave under the conditions specified in policy. A pharmacy resident must first use available paid time off. Once available paid time off is exhausted, subsequent leave will be unpaid. The cost to continue benefits during this time will be collected in arrears, as applicable and in accordance with payroll standard procedures.

A pharmacy resident may be required to extend the training period for any dates of absence in excess of allowable paid time off. During the extension, the pharmacy resident will receive regular salary and benefits except for paid time off allowance.

#### **Bereavement**

The phrmacy resident may take up to three workdays off with pay as a bereavement leave benefit, in the event of the death of an immediate family member, parent's loss of a pregnancy, or as otherwise outlined in policy. Days do not need to be taken consecutively. Implementation of this benefit is as outlined in the current Trinity Health Human Resources Ministry-Wide Policy No. 1015: Bereavement Leave Benefit.

# **Jury Duty**

Loyola supports a pharmacy resident's civic duty and responsibility to serve on a jury and will follow Trinitty Health Human Resources Ministry-Wide Policy No. 1018: Jury Duty Benefit. When a pharmacy resident is selected for jury duty, they should notify the RPD immediately. Jury duty does not affect continuous stipends or benefits.



#### **Parking**

Loyola pharmacy residents are required to park their vehicles in designated parking areas. Pharmacy residents are not permitted to park in areas designated for patient and visitor use (unless authorization is first granted by the Parking Office).

All parking lot assignments are made by the Parking Office. Parking fees are the responsibility of the pharmacy resident. Fees will be assessed in accordance with the Parking Department's standard fee schedule.

All penalties for violation of parking assignments will be the responsibility of the pharmacy resident.

Pharmacy residents reporting after hours for emergency call-in/special assignment may request that an officer accompany them to their parking space and escort them back to the hospital.

# **Employee Assistance Program**

Loyola provides the Employee Assistance Program (EAP) as a confidential way to aid individuals experiencing personal problems that may benefit from professional help. EAP is one of the ways that Loyola demonstrates its commitment to and investment in its colleagues, and there is no charge for the services provided directly by EAP.

Some of the mental well-being issues the EAP handles include marital concerns, family conflict, alcohol/drug abuse, emotional difficulties, and job stress. The service provides free assessment and short-term counseling when appropriate. In addition, every effort is made to locate local referral resources that will provide affordable services to Loyola employees and residents. In addition to mental well-being support, resources are available for emotional, spiritual, physical, financial, social, and vocational needs. Detailed information on available services and how to access them is available through HR4U and on SharePoint.

## **Loyola University Center for Health and Fitness**

Membership for the Loyola athletic/recreational facilities is an annual fee for all LUC and LUMC faculty and staff. These fees may be paid through payroll deductions. For further information, contact the Center for Health and Fitness at 327.2348.

# **Workers' Compensation**

Pharmacy residents are covered by Workers' Compensation for any work-related injury, illness, or exposure incurred on the job while performing regular duties. Occupational injuries, illnesses, and exposures are defined as those that arise out of and in the course and scope of your employment. Workers Compensation covers hospital expenses, medical expenses and provides Temporary Total Disability income for occupational injuries, illnesses, and exposures. All pharmacy residents are eligible for this coverage from the first day of residency.

Injuries or accidents that occur while traveling to and from work or when moonlighting are not covered.

If a pharmacy resident is injured at work, he/she MUST get medical help immediately at the current facility. During the day, he/she must go to Employee Health. When Employee Health is closed, injured pharmacy residents should be seen in the emergency room. The pharmacy resident must report the injury to Loyola University Medical Center Employee Health Office within 24 hours. If



off-hours, contact Employee Health by leaving a message including resident's name and pager number.

If a pharmacy resident receives medical attention for an occupational injury, illness, or exposure and receives a bill for those services, it is the pharmacy resident's responsibility to send the bill to the Workers' Compensation Coordinator in Human Resources. Any follow-up medical care MUST be coordinated through Employee Health and be provided through the Worker's Compensation program. Although the resident is not obligated to receive continued treatment at this institution, benefits may be delayed or denied if his/her physician does not furnish information on a timely basis to Loyola's Employee Health Office.

Failure to follow the above procedures may result in rejection of Workers' Compensation claim and denial of any future claims for that particular incident.

Any injury, illness, or exposure incurred as a result of activities directly related to assignment should be reported by completing an incident report online and promptly contacting the Employee Health Office. If you have any questions, call Employee Health at 708-216-3400.

#### **Education Assistance Benefit**

Loyola pharmacy residents who meet eligibility requirements in accordance with policy may qualify for tuition assistance. Pharmacy residents interested in such benefits can refer to Trinity Health Human Resources Operating Policy No. 480: Tuition Reimbursement for additional information.

Loyola is required to report the amount of tuition credited on behalf of employees and their dependents as taxable earnings to the employee in accordance with Internal Revenue Service (IRS) requirements and tax regulations.